# EDGAR Filing Document

**Accession Number:** 0001804591
**File Stem:** 0001193125-25-211327
**Filing Date:** 2025-9
**Character Count:** 249281
**Document Hash:** 39296986fcd05a29820482385f7ac3d9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-211327.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0001193125-25-211327

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 77

**CONFORMED PERIOD OF REPORT**: 20250922

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250922

**DATE AS OF CHANGE**: 20250922

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chrome Holding Co.
- **CENTRAL INDEX KEY:** 0001804591
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 871240344
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39587
- **FILM NUMBER:** 251330186

**BUSINESS ADDRESS:**
- **STREET 1:** 870 MARKET STREET
- **STREET 2:** ROOM 415
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94102
- **BUSINESS PHONE:** (650) 938-6300

**MAIL ADDRESS:**
- **STREET 1:** 870 MARKET STREET
- **STREET 2:** ROOM 415
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 23andMe Holding Co.
- **DATE OF NAME CHANGE:** 20210617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VG Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200915

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virgin Group Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200909

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): September 22, 2025

## Chrome Holding Co.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39587** | **87-1240344** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

#### 870 Market Street, Room 415

#### San Francisco, California 94102

#### (Address of principal executive offices, including zip code)

#### Registrant's telephone number, including area code: (650) 938-6300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure.**  |

---

As previously disclosed, on March 23, 2025, Chrome Holding Co. (formerly known as 23andMe Holding Co.), a Delaware corporation (the "Company"), and certain of its subsidiaries (together with the Company, the "Debtors") filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Eastern District of Missouri (the "Court").

#### Prior Monthly Operating Reports
On April 30, 2025, May 30, 2025, June 30, 2025, July 31, 2025, and September 2, 2025, the Company filed with the Court its monthly operating report for the periods ended March 31, 2025, April 30, 2025, May 31, 2025, June 30, 2025, and July 31, 2025, respectively (collectively, the "Monthly Operating Reports"). The Monthly Operating Reports are attached hereto as Exhibits 99.1, 99.2, 99.3, 99.4, and 99.5. This Current Report on Form 8-K (including the exhibits attached hereto, the "Form 8-K") will not be deemed an admission as to the materiality of any herein. The Monthly Operating Reports and other documents filed with the Court are available for review and free of charge online at https://restructuring.ra.kroll.com/23andMe.

#### Future Monthly Operating Reports
The Debtors are required, and will continue, to file monthly operating reports with the Court at or around the end of each month during which the Chapter 11 Cases remain pending. Future monthly operating reports will be similarly available for review and free of charge online at https://restructuring.ra.kroll.com/23andMe. Such reports may be filed with the Court without the filing of an accompanying Current Report on Form 8-K. In addition, investors are directed to visit https://restructuring.ra.kroll.com/23andMe for other materials that are provided with respect to the Debtors from time to time in connection with the Chapter 11 Cases.

The information in this report furnished pursuant to Item 7.01, including Exhibits 99.1, 99.2, 99.3, 99.4, and 99.5 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It shall not be deemed to be incorporated by reference into any of the Company's filings under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

#### Additional Information on the Chapter 11 Cases
Court filings and information about the Chapter 11 Cases can be found at a website maintained by the Company's claims agent Kroll at https://restructuring.ra.kroll.com/23andMe, by calling (888) 367-7556, or by sending an email to 23andMeInfo@ra.kroll.com. The website addresses set forth herein are included as inactive textual references only. The documents and other information available via website or elsewhere are not part of this Form 8-K and will not be deemed incorporated herein.

#### Cautionary Note Regarding the Company's Common Stock
The Company cautions that trading in the Company's Class A common stock, $0.0001 par value per share (the "Common Stock") during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for the Company's Common Stock may bear little or no relationship to the actual recovery, if any, by holders of the Common Stock in the Chapter 11 Cases. The Company cannot assure investors of the liquidity of an active trading market, the ability to sell shares of the Common Stock when desired, or the prices that an investor may obtain for the shares of the Common Stock.

#### Cautionary Note Regarding the Monthly Operating Reports
The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Monthly Operating Reports, which were not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The Monthly Operating Reports are limited in scope, cover a limited time period, and have been prepared solely for the purpose of complying with the reporting requirements of the Court. The Monthly Operating Reports were not audited or reviewed by independent accountants, were not prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"), are in a format prescribed by applicable bankruptcy rules and guidelines, and are subject to future adjustment and reconciliation. Furthermore, the monthly financial information contained in the Monthly Operating Reports has not been subjected to the same level of accounting review and testing that the Debtors apply when preparing their quarterly and annual consolidated financial information in accordance with GAAP.

------

Accordingly, upon the application of such procedures, the Debtors believe that the financial information may be subject to change, and these changes could be material. There can be no assurance that, from the perspective of an investor or potential investor in the Company's securities, the Monthly Operating Reports are complete. Results and projections set forth in the Monthly Operating Reports should not be viewed as indicative of future results.

#### Cautionary Note Regarding Forward-Looking Statements
This Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements, other than statements of historical fact, included or incorporated in this document are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "predicts," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company's current expectations and projections about future events and various assumptions. The Company cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of the Company), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements, which could include the following: risks and uncertainties relating to the Chapter 11 Cases, including but not limited to, the Company's ability to obtain Court approval with respect to motions in the Chapter 11 Cases, the effects of the Chapter 11 Cases on the Company and on the interests of various constituents, Court rulings in the Chapter 11 Cases and the outcome of the Chapter 11 Cases in general, the length of time the Company will operate under the Chapter 11 Cases, risks associated with any third-party motions in the Chapter 11 Cases, the adverse effects of the Chapter 11 Cases on the Company's liquidity or results of operations and increased legal and other professional costs necessary to execute the Company's Chapter 11 Cases; trading price and volatility of the Common Stock; and the continuation of trading of the Common Stock on the OTC Pink Market, including whether broker-dealers will continue to provide public quotes of the Common Stock on the OTC Pink Market and whether the trading volume of the Common Stock will be sufficient to provide for an efficient trading market. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as filed with the SEC, and as revised and updated by the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this document and, except as may be required by law, the Company undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description of Exhibit** |
| 99.1 | [Monthly Operating Report of Chrome Holding Co. for the period ended March 31, 2025 filed with the United States Bankruptcy Court for the Eastern District of Missouri](d847630dex991.htm) |
| 99.2 | [Monthly Operating Report of Chrome Holding Co. for the period ended April 30, 2025 filed with the United States Bankruptcy Court for the Eastern District of Missouri](d847630dex992.htm) |
| 99.3 | [Monthly Operating Report of Chrome Holding Co. for the period ended May 31, 2025 filed with the United States Bankruptcy Court for the Eastern District of Missouri](d847630dex993.htm) |
| 99.4 | [Monthly Operating Report of Chrome Holding Co. for the period ended June 30, 2025 filed with the United States Bankruptcy Court for the Eastern District of Missouri](d847630dex994.htm) |
| 99.5 | [Monthly Operating Report of Chrome Holding Co. for the period ended July 31, 2025 filed with the United States Bankruptcy Court for the Eastern District of Missouri](d847630dex995.htm) |
| 104 | Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CHROME HOLDING CO.** | **CHROME HOLDING CO.** |
| Date: September 22, 2025 | By: | /s/ Joseph Selsavage |
|  |  | Name: Joseph Selsavage |
|  |  | Title: Chief Executive Officer and Chief Financial and Accounting Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**UNITED STATES BANKRUPTCY COURT** 

**EASTERN DISTRICT OF MISSOURI** 

**EASTERN DIVISION** 

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;In re: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chapter 11 |
| &nbsp;&nbsp;&nbsp;23ANDME HOLDING CO., *et al.*,<sup>1</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Case No. 25-40976-357 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debtors. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Jointly Administered) |

---

**GLOBAL NOTES AND STATEMENTS OF LIMITATIONS, METHODOLOGY,** 

**AND DISCLAIMERS REGARDING THE DEBTORS' MONTHLY OPERATING REPORT** 

On March 23, 2025 (the "<u>Petition Date</u>"), the above-captioned debtors and debtors in possession (collectively, the "<u>Debtors</u>") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "<u>Bankruptcy Code</u>") in the United States Bankruptcy Court for the Eastern District of Missouri (the "<u>Court</u>"), thereby commencing these chapter 11 cases. The Debtors are operating their business and managing their property as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. On March 27, 2025, the Court entered an order authorizing the joint administration of these chapter 11 cases pursuant to rule 1015(b) of the Federal Rules of Bankruptcy Procedure [Docket No. 105]. On April 3, 2025, the United States Trustee for the Eastern District of Missouri appointed an official committee of unsecured creditors pursuant to section 1102(a)(1) of the Bankruptcy Code (the "<u>Committee</u>") [Docket No. 159].

The following global notes and statements of limitations, methodology, and disclaimers should be referred to and referenced in connection with any review of this MOR (as defined below).

**1.** **General Methodology.** The Debtors are filing this consolidated monthly operating report
(" <u>MOR</u> ") for the period from March 24, 2025, through and including March 31, 2025 (the " <u>Reporting Period</u> "), solely for the purpose of complying with the monthly reporting requirements applicable
in the Debtors' chapter 11 cases. This MOR is (a) unaudited, has not been prepared in accordance with (i) Generally Accepted Accounting Principles in the United States (" <u>U.S. GAAP</u> ") and does not include all of the
information and footnotes required by U.S. GAAP, or (ii) federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any period reporting requirements thereunder
and (b) remains subject to future adjustments. This MOR is not intended to reconcile any financial statements otherwise prepared or distributed by the Debtors. This MOR should not be relied upon by any person for information relating to the
current or future financial condition of the Debtors or their affiliates, the occurrence or non-occurrence of any event, or the performance of any of the

<sup>1</sup> The Debtors in each of these cases, along with the last four digits of each Debtor's federal tax identification number, are: 23andMe Holding Co. (0344), 23andMe, Inc. (7371), 23andMe Pharmacy Holdings, Inc. (4690), Lemonaid Community Pharmacy, Inc. (7330), Lemonaid Health, Inc. (6739), Lemonaid Pharmacy Holdings Inc. (6500), LPharm CS LLC (1125), LPharm INS LLC (9800), LPharm RX LLC (7746), LPRXOne LLC (3447), LPRXThree LLC (3852), and LPRXTwo LLC (1595). The Debtors' service address for purposes of these chapter 11 cases is: 870 Market Street, Room 415, San Francisco, CA 94102. 

------

Debtors or their affiliates as the results of operations addressed herein are not necessarily indicative of results that may be expected from any other period or for the full year and may not reflect the combined results of the Debtors' operations, the Debtors' financial position, or the Debtors' schedule of receipts and disbursements in the future. The preparation of this MOR required the Debtors to make commercially reasonable estimates and assumptions with respect to the reported amounts of assets and liabilities at month end and the reported amounts of revenues and expenses during the applicable reporting periods. Actual results could differ materially from such estimates.

**2.** **Basis of Presentation.** In preparing this MOR, the Debtors relied on financial information from the books and records available to them at the time of such preparation. The financial information contained herein is derived from the Debtors' books and records without, among other things, all adjustments or reclassifications that may be
necessary or typical for consolidated financial statements or to accord with U.S. GAAP. As a result, all information contained herein is subject to change, which could be material. Although the Debtors made commercially reasonable efforts to ensure
the material accuracy and completeness of this MOR and because the Debtors' accounting systems were developed to produce consolidated financial statements by business unit rather than financial statements by legal entity, it is possible that
not all assets, liabilities, income, or expenses have been attributed to the correct legal entity.

The information contained in this MOR has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtors believe that the financial information presented in this MOR could be subject to material change.

For the reasons discussed above, there can be no assurance that the financial information presented herein is complete, and readers are strongly cautioned not to place undue reliance on this MOR. Moreover, the results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the results of operations, financial position and cash flows of the Debtors in the future.

**3.** **Reporting Period.** Unless otherwise noted herein, this MOR generally reflects the Debtors' books
and records for the applicable Reporting Period. Unless otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

**4.** **Consolidated Entity Accounts Payable and Disbursement Systems.** Receivables and payables among the
Debtors and their non-Debtor affiliates<sup>2</sup> are reported per the Debtors' unaudited books and records. As described more fully in the *Final Order (I) Authorizing (A) Continued Use of Cash Management System, (B) Maintenance of Bank Accounts and Business Forms, (C) Performance of Intercompany Transactions, And (D) Certain Prepetition Obligations to Be Honored; (II) Granting Administrative Expense Priority Status to Postpetition Intercompany Claims Against The Debtors; And (III) Granting Related Relief* [Docket No. 297], the Debtors utilize an integrated, centralized cash **  management system in the ordinary course of business to collect, concentrate, and disburse funds generated from their operations. Cash is being received and
disbursed by the Debtors during these chapter 11 cases in a manner consistent with the Debtors' historical cash management practices.

**5.** **Accuracy.** The financial information disclosed herein was not prepared in accordance with federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling,
or transferring claims against or interests in the Debtors should evaluate this financial information in light

<sup>2</sup> Non-Debtor affiliates exclude any controlling shareholder of 23andMe Holding Co.

------

of the purposes for which it was prepared. The Debtors and their advisors are not liable for and undertake no responsibility (i) to indicate variations from state, federal, or other securities laws or (ii) for any evaluations of the Debtors, including of their financial condition, based on the information provided in this MOR or any other information.

**6.** **Debtor in Possession Financing.** On April 23, 2025, the Court entered the *Final Order* (*A) Authorizing the Debtors to Obtain Postpetition Financing, Grant Liens, Provide Superpriority Administrative Expense Claims and Use Cash Collateral, (B) Modifying the Automatic Stay, and (C) Granting Related Relief* [Docket No. 313] (the " <u>DIP Order</u> "), authorizing the Debtors, jointly and **  severally, to obtain a non-amortizing, priming, super-priority senior secured postpetition credit
facility (the " <u>DIP Facility</u> ") in an aggregate principal amount of up to $35,000,000 of which (a) up to $10 million became available following entry of the DIP Order and (b) the remaining $25 million will be
available upon the Court's entry of an order on or before May 7, 2025, authorizing and approving a stalking horse purchase agreement that (i) is executed, effective, and binding on all parties thereto and (ii) either (A) is
approved by the DIP Lender (as defined below) in its reasonable discretion or (B)(1) would generate cash proceeds (as evidenced by financing sources reasonably acceptable to the DIP Lender) sufficient for the payment in full of the DIP Obligations
(as defined in the DIP Order) upon closing of a sale, (2) closes on or before June 30, 2025, and (3) requires, pursuant to a Court order, the payment in full of the DIP Obligations, in each case, subject to the terms and conditions
set forth in DIP Order and that certain *Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement* by and among the Debtors, as
Borrowers, and JMB Capital Partners Lending, LLC or its **  permitted designees or assignees, as Lender (the " <u>DIP Lender</u> "). The Debtors did not borrow any amounts under the DIP Facility in the Reporting Period.

Please refer to the DIP Order for additional details.

**7.** **Payment of Prepetition Claims Pursuant to First Day Orders.** Following the Petition Date, the Court entered various orders authorizing, but not directing, the Debtors to, among other things, pay certain prepetition: (a) charges assessed by the Debtors' banks; (b) insurance obligations; (c) employee wages, salaries,
and related items (including employee benefit programs); (d) taxes and assessments; (e) customer program obligations; and (f) critical vendor obligations (collectively, the " <u>First Day</u> <u>Orders</u> "). To the extent any
payments were made during the Reporting Period on account of prepetition claims pursuant to the authority granted to the Debtors by the Court under the First Day Orders, such payments have been included in this MOR (subject to the notes and
statements and limitations provided herein).

**8.** **Reservation of Rights.** The Debtors reserve all rights to amend or supplement this MOR in all
respects, as may be necessary or appropriate. Nothing contained in this MOR shall constitute a waiver of any of the Debtors' rights or an admission with respect to their chapter 11 cases.

**9.** **Insiders.** Information regarding the individuals listed as "insiders" in this MOR have been
included for informational purposes only. The Debtors do not take any position with respect to, and reserve all rights with respect to: (a) such person's influence over or control of the Debtors, (b) the management
responsibilities or functions of such individual, (c) the decision-making or corporate authority of such individual, and (d) whether such individual could successfully argue that he or she is not an "insider" under applicable
law, including any state, federal, or other securities law, or with respect to any theories of liability or for any other purpose.

**10.** **Currency.** All amounts shown in this MOR are in United States dollars unless otherwise stated.

------

**11.** **MOR Information Requests.** The Debtors and/or their advisors are managing an email address to which parties may send requests for additional information from the Debtors regarding the information contained in this and all other MORs. For any such requests, please send an email to <u>23andMeInfo@ra.kroll.com</u>.

**12.** **Specific MOR Disclosures.** 

**Notes to Part 1: Cash Receipts and Disbursements** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Figures include cash as reported in the Debtors' bank statements. Reconciliation differences will exist
between bank statement balances and balance sheet cash balances due to ordinary course timing differences between payment execution in the Debtors' financial system and disbursement of funds from Debtor bank accounts.

**Notes to Part 2: Asset and Liability Status** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• See "Basis of Presentation" notes above regarding certain adjustments or reclassifications applied at
a consolidated level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Because the Debtors' existing recording systems were not designed to distinguish between pre- and postpetition liabilities, the Debtors have commenced a process to distinguish between pre- and postpetition liabilities, the results of which are reflected in this
MOR. As the Debtors continue this process and additional information becomes available, the allocation of liabilities between prepetition and postpetition periods may change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Items (k–m)</u>: Prepetition liabilities (*i.e.*, items (k), (l), and (m)) reflect liabilities
included in "Liabilities subject to compromise" on the Debtors' balance sheet as well as other prepetition liabilities that may be uncompromised pursuant to the relief granted via the First Day Orders. The Debtors' inclusion
or exclusion of any amounts in the presentation of "liabilities subject to compromise" in the Balance Sheet is done solely to enable the debtors to expeditiously prepare this MOR pursuant to the Debtors' reporting obligations and
does not indicate a view, of the Debtors or of any other person, as to whether and to what extent the respective liabilities may be impaired.

**Notes to Part 4: Income Statement** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• See "Basis of Presentation" notes above regarding certain adjustments or reclassifications applied at
a consolidated level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This MOR has not been subject to certain quarterly or annual adjustment procedures, including income tax
provision and impairment assessment procedures. The information presented herein may materially differ if such procedures were applied.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (b)</u>: "Cost of revenue" on the Debtors' balance sheet is classified as a cost of
goods sold (*i.e.*, item (b)). Cost of Revenue includes the day-to-day costs of operating the business like facility and equipment costs, and depreciation and
amortization.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (e)</u>: Depreciation and Amortization are netted with the totals for the Cost of Service, General and
Administrative and Other expenses and have not been broken out as a separate line item.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (f)</u>: Other expenses (*i.e.*, item (f)) include Research and Development expenses and other
income.

**Notes to Part 5: Professional Fees and Expenses** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors did not make any payments to any restructuring professionals or any professionals of the Committee
during this Reporting Period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (c)</u>: Part 5(c) provides the total of professional fees and expenses paid presented in Part 5(a) and
Part 5(b), as well as professional fees and expenses paid for professionals employed by the Committee.

------

**Notes to Part 6: Postpetition Taxes** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the ordinary course of business, the Debtors collect, withhold, and incur income taxes, franchise taxes, sales
and use taxes, personal property taxes, foreign taxes, and other governmental and regulatory taxes, penalties, interests, assessments, and fees.

**Notes to Part 7: Questionnaire** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (a)</u>: Pursuant to the relief granted in the Debtors' various First Day Orders, the Debtors have
made payments on account of prepetition debts as they come due in the ordinary course of business. Where applicable, details of these payments have been delivered to the required notice parties pursuant to the reporting requirements set forth in the
First Day Orders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (g)</u>: Please refer to the "Debtor in Possession Financing" notes above regarding approved
postpetition financing.

------

![LOGO](g847630dsp011.jpg)

UNITED STATES BANKRUPTCY COURT Eastern DISTRICT OF Missouri In Re. 23andMe, Inc. § Case No. 25-40977 § § Lead Case No. 25-40976 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 03/31/2025 Petition Date: 03/23/2025 Months Pending: 0 Industry Classification: 6 2 1 5 Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Employees (current): 257 Debtor's Full-Time Employees (as of date of order for relief): 262 Supporting Documentation (check all that are attached): (For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement) Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Thomas H. Riske Thomas H. Riske Signature of Responsible Party Printed Name of Responsible Party 04/30/2025 Date 120 S. Central Avenue, Suite 1800, St. Louis, Missouri 63105 Address STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

UST Form 11-MOR (12/01/2021) 1

------

![LOGO](g847630dsp012.jpg)

Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $52,049,982 b. Total receipts (net of transfers between accounts) $2,203,742 $2,203,742 c. Total disbursements (net of transfers between accounts) $2,038,561 $2,038,561 d. Cash balance end of month (a+b-c) $52,215,164 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation (c+e) $2,038,561 $2,038,561 Part 2: Asset and Liability Status Current Month (Not applicable to Individual Debtors. See Instructions.) a. Accounts receivable (total net of allowance) $1,420,651 b. Accounts receivable over 90 days outstanding (net of allowance) $750,000 c. Inventory (Book Market Other (attach explanation)) $15,386,219 d Total current assets $67,610,388 e. Total assets $159,270,267 f. Postpetition payables (excluding taxes) $783,740 g. Postpetition payables past due (excluding taxes) $0 h. Postpetition taxes payable $69,626 i. Postpetition taxes past due $0 j. Total postpetition debt (f+h) $853,366 k. Prepetition secured debt $224,364 l. Prepetition priority debt $202,491 m. Prepetition unsecured debt $185,134,082 n. Total liabilities (debt) (j+k+l+m) $186,414,302 o. Ending equity/net worth (e-n) $-27,144,035 Part 3: Assets Sold or Transferred Current Month a. Total cash sales price for assets sold/transferred outside the ordinary course of business $0 $0 b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business $0 $0 c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $0 $0 Part 4: Income Statement (Statement of Operations) Current Month (Not generally applicable to Individual Debtors. See Instructions.) a. Gross income/sales (net of returns and allowances) $2,356,754 b. Cost of goods sold (inclusive of depreciation, if applicable) $1,889,812 c. Gross profit (a-b) $466,942 d. Selling expenses $869,195 e. General and administrative expenses $4,341,689 f. Other expenses $2,558,995 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $-50,544 i. Taxes (local, state, and federal) $0 j. Reorganization items $13,028,647 k. Profit (loss) $-20,281,040 $-20,281,040

UST Form 11-MOR (12/01/2021) 2

------

![LOGO](g847630dsp013.jpg)

UST Form 11-MOR (12/01/2021) 3 Debtor's Name 23andMe, Inc. Case No. 25-40977 Part 5: ProfessExpenses Approved Current Month Approved Cumulative Paid Current Month Paid Cumulative a. Debtor's professional fees & expenses (bankruptcy) Aggregate Total $0 $0 $0 $0 Itemized Breakdown by Firm Firm Name Role i Alvarez & Marsal North Ameri Financial Professional $0 $0 $0 $0 ii Carmody MacDonald P.C. Local Counsel $0 $0 $0 $0 iii Goodwin Procter LLP Special Counsel $0 $0 $0 $0 iv Kroll Restructuring AdministratOther $0 $0 $0 $0 v Lewis Rice LLC Special Counsel $0 $0 $0 $0 vi Moelis & Company, LLC Financial Professional $0 $0 $0 $0 vii Paul, Weiss, Rifkind, Wharton &Lead Counsel $0 $0 $0 $0 viii ix x xi xii xiii xiv xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv

UST Form 11-MOR (12/01/2021) 3

------

![LOGO](g847630dsp014.jpg)

xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii

UST Form 11-MOR (12/01/2021) 4

------

![LOGO](g847630dsp015.jpg)

UST Form 11-MOR (12/01/2021) 5 Debtor's Name 23andMe, Inc. Case No. 25-40977 lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci Approved Current Month Approved Cumulative Paid Current Month Paid Cumulative b. Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total $0 $0 $0 $0 Itemized Breakdown by Firm Firm Name Role i BDO USA LLP Other $0 $0 $0 $0 ii Captiva Advisory, Inc. Other $0 $0 $0 $0 iii Deloitte & Touche LLP Other $0 $0 $0 $0 iv Duane Morris LLP Other $0 $0 $0 $0 v FisherBroyles, LLP Other $0 $0 $0 $0 vi Foley & Lardner LLP Other $0 $0 $0 $0 vii Frank, Rimerman Co LLP Other $0 $0 $0 $0 viii Gibson, Dunn & Crutcher LLP Other $0 $0 $0 $0 ix Greenberg Traurig LLP Other $0 $0 $0 $0 x Hintze Law PLLC Other $0 $0 $0 $0 xi KPMG LLP Other $0 $0 $0 $0 xii McDonnell Boehnen Hulbert & LLP Other $0 $0 $0 $0 xiii Morgan, Lewis & Bockius LLP Other $0 $0 $0 $0 8xiv476O3sle0r -H0o0sk1in & H a r c o u r t L L 1P9OStheerp25 11:10 P$a0ge 15 $0 $0 $0

UST Form 11-MOR (12/01/2021) 5

------

![LOGO](g847630dsp016.jpg)

UST Form 11-MOR (12/01/2021) 6 Debtor's Name 23andMe, Inc. Case No. 25-40977 xv Quarles & Brady LLP Other $0 $0 $0 $0 xvi Reevemark, LLC Other $0 $0 $0 $0 xvii Ryan, LLC Other $0 $0 $0 $0 xviii Scale Strategy Operations LLC Other $0 $0 $0 $0 xix Sheppard Mullin Other $0 $0 $0 $0 xx Wilson Sonsini Goodrich & Ro Other $0 $0 $0 $0 xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv 8lvi47630-001 19Sep25 11:10

UST Form 11-MOR (12/01/2021) 6

------

![LOGO](g847630dsp017.jpg)

lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii

UST Form 11-MOR (12/01/2021) 7

------

![LOGO](g847630dsp018.jpg)

xcix c c. All professional fees and expenses (debtor & committees) $0 $0 $0 $0 Part 6: Postpetition Taxes Current Month Cumulative a. Postpetition income taxes accrued (local, state, and federal) $0 $0 b. Postpetition income taxes paid (local, state, and federal) $0 $0 c. Postpetition employer payroll taxes accrued $50,836 $50,836 d. Postpetition employer payroll taxes paid $88,354 $88,354 e. Postpetition property taxes paid $0 $0 f. Postpetition other taxes accrued (local, state, and federal) $18,790 $18,790 g. Postpetition other taxes paid (local, state, and federal) $0 $0 Part 7: Questionnaire—During this reporting period: a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No b. Were any payments made outside the ordinary course of business Yes No without court approval? (if yes, see Instructions) c. Were any payments made to or on behalf of insiders? Yes No d. Are you current on postpetition tax return filings? Yes No e. Are you current on postpetition estimated tax payments? Yes No f. Were all trust fund taxes remitted on a current basis? Yes No g. Was there any postpetition borrowing, other than trade credit? Yes No (if yes, see Instructions) h. Were all payments made to or on behalf of professionals approved by Yes No N/A the court? i. Do you have: Worker's compensation insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) General liability insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) j. Has a plan of reorganization been filed with the court? Yes No k. Has a disclosure statement been filed with the court? Yes No l. Are you current with quarterly U.S. Trustee fees as Yes No set forth under 28 U.S.C. § 1930?

UST Form 11-MOR (12/01/2021) 8

------

![LOGO](g847630dsp019.jpg)

Part 8: Individual Chapter 11 Debtors (Only) a. Gross income (receipts) from salary and wages $0 b. Gross income (receipts) from self-employment $0 c. Gross income from all other sources $0 d. Total income in the reporting period (a+b+c) $0 e. Payroll deductions $0 f. Self-employment related expenses $0 g. Living expenses $0 h. All other expenses $0 i. Total expenses in the reporting period (e+f+g+h) $0 j. Difference between total income and total expenses (d-i) $0 k. List the total amount of all postpetition debts that are past due $0 l. Are you required to pay any Domestic Support Obligations as defined by 11 Yes No U.S.C § 101(14A)? m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A Privacy Act Statement 28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F). I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate. /s/ Joe Selsavage Joe Selsavage Signature of Responsible Party Printed Name of Responsible Party Interim Chief Executive Officer and Chief Financial and 04/30/2025 Title Date

UST Form 11-MOR (12/01/2021) 9

------

![LOGO](g847630dsp020.jpg)

UST Form 11-MOR (12/01/2021) 10

------

![LOGO](g847630dsp021.jpg)

UST Form 11-MOR (12/01/2021) 11

------

![LOGO](g847630dsp022.jpg)

UST Form 11-MOR (12/01/2021) 12

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 1** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 3/24/2025 - 3/31/2025 |
| **Cash Receipts and Disbursements** | **Cash Receipts and Disbursements** | **Cash Receipts and Disbursements** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **25-40977<br>23andMe,**<br> **Inc.** | **25-40976<br>23andMe**<br> **Holding<br>Co.** | **25-40978<br>23andMe**<br> **Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid**<br> **Community<br>Pharmacy,<br>Inc** | **25-40980<br>Lemonaid**<br> **Health,**<br> **Inc.** | **25-40981<br>Lemonaid**<br> **Pharmacy<br>Holdings<br>Inc.** | **25-40982<br>LPharm**<br> **CS**<br> **LLC** | **25-40983<br>LPharm**<br> **INS**<br> **LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40975<br>LPRXOne<br>LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  Beginning bank cash balance | $52050 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total receipts | 2204 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total disbursements | (2039) |  |  |  |  |  |  |  |  |  |  |  |
|  **Ending bank cash balance** | $**52215** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 2** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 3/24/2025 - 3/31/2025 |
| **Balance Sheet** | **Balance Sheet** | **Balance Sheet** |

---

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Consolidated** | **25-40977**<br> **23andMe,<br>Inc.** | **25-40975**<br> **LPRXOne<br>LLC** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40976**<br> **23andMe**<br> **Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings<br>Inc.** | **25-40982**<br> **LPharm<br>CS**<br> **LLC** | **25-40983**<br> **LPharm<br>INS**<br> **LLC** | **25-40984**<br> **LPharm<br>RX**<br> **LLC** | **25-40986**<br> **LPRXTwo**<br> **LLC** | **25-40985**<br> **LPRXThree**<br> **LLC** |
|  **Assets** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **Current assets:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Cash and Cash Equivalents | $37355 | $37355 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Accounts receivable | 1421 | 1421 |  |  |  |  |  |  |  |  |  |  |  |
|  Prepaid Expenses | 13475 | 13448 |  | 26 |  |  |  |  |  |  |  |  |  |
|  Inventory | 15593 | 15386 | 207 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current assets** | **67844** | **67610** | **207** | **26** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Property and equipment, net | $1258 | $1033 | $225 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Lease right-of-use assets, net | 533 | 533 |  |  |  |  |  |  |  |  |  |  |  |
|  Restricted cash | 13938 | 13938 |  |  |  |  |  |  |  |  |  |  |  |
|  Intangible assets, net | 44731 | 44731 |  |  |  |  |  |  |  |  |  |  |  |
|  Other assets | 31589 | 31424 | 165 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total assets** | $**159894** | $**159270** | $**597** | $**26** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |
|  **Liabilities** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **Current liabilities:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Accounts payable and accrued expenses | $64091 | $63974 | $12 | $104 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Deferred revenue | 49347 | 49347 |  |  |  |  |  |  |  |  |  |  |  |
|  Lease Liabilities | 68428 | 68428 |  |  |  |  |  |  |  |  |  |  |  |
|  Tax Payable | 202 | 202 |  |  |  |  |  |  |  |  |  |  |  |
|  Other Current Liabilities | 2579 | 2579 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current liabilities** | **184647** | **184530** | **12** | **104** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Other Liabilities | $1814 | $1814 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total liabilities** | **186461** | **186345** | **12** | **104** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Common Stock | $3 | $3 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Additional paid-in capital | 2427228 | 2427228 |  |  |  |  |  |  |  |  |  |  |  |
|  Accumulated Deficit-Retained Earnings | (67064) | (67064) |  |  |  |  |  |  |  |  |  |  |  |
|  Accumulated Deficit-Net Income | (2386734) | (2386734) |  |  |  |  |  |  |  |  |  |  |  |
|  **Total liabilities and equity** | $**159894** | $**159777** | $**12** | $**104** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

**Notes:** The Debtors maintain their books and records on a consolidated basis in the ordinary course of business, however, this MOR was prepared on an entity-by-entity basis. Accordingly, column "Consolidated" was included to provide a consolidated view of the Balance Sheet for reconciliation purposes only.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 3** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 3/24/2025 - 3/31/2025 |
| **Income Statement** | **Income Statement** | **Income Statement** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **25-40977<br>23andMe,<br>Inc.** | **25-40975<br>LPRXOne<br>LLC** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40976**<br> **23andMe<br>Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings<br>Inc.** | **25-40982<br>LPharm<br>CS LLC** | **25-40983<br>LPharm<br>INS<br>LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  **Revenue:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Total consumer services revenue | $2192 | $— | $80 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total research services and other revenue | 164 |  |  |  |  |  |  |  |  |  |  |  |
|  Total product revenue |  | 444 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total revenue** | **2357** | **444** | **80** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Expenses:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Cost of revenue | $1890 | $52 | $5 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Sales and marketing | 869 | 146 | 280 |  |  |  |  |  |  |  |  |  |
|  General and administrative | 4342 | 97 | 85 |  |  |  |  |  |  |  |  |  |
|  Research and developmen | 2722 | 1 | 3 |  |  |  |  |  |  |  |  |  |
|  Restructuring and other related cost | 13029 |  | 22 |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total expenses** | **22852** | **296** | **395** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Income (Loss) from operations | $(20495) | $148 | $(315) | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  **Interest and other (expense) income:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Total-Interest income | $51 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total - Other (expense) incom | 163 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total interest and other (expense) income** | **214** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Net income (loss)** | $**(20281)** | $**148** | $**(315)** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 4** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 3/24/2025 - 3/31/2025 |
| **Accounts Receivable Aging** | **Accounts Receivable Aging** | **Accounts Receivable Aging** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Current - 31** | **32 - 61** | **62 - 91** | **92+** | **Gross AR** | **Allowance for**<br> **Doubtful**<br> **Accounts** | **Net AR** |
| 25-40977 | 23andMe, Inc. | $784 | $387 | $– $| 750 | $1921 | $500 | $1421 |
| 25-40976 | 23andMe Holding Co. |  |  | – |  |  |  |  |
| 25-40978 | 23andMe Pharmacy Holdings, Inc. |  |  | – |  |  |  |  |
| 25-40979 | Lemonaid Community Pharmacy, Inc |  |  | – |  |  |  |  |
| 25-40980 | Lemonaid Health, Inc. |  |  | – |  |  |  |  |
| 25-40981 | Lemonaid Pharmacy Holdings Inc. |  |  | – |  |  |  |  |
| 25-40982 | LPharm CS LLC |  |  | – |  |  |  |  |
| 25-40983 | LPharm INS LLC |  |  | – |  |  |  |  |
| 25-40984 | LPharm RX LLC |  |  | – |  |  |  |  |
| 25-40975 | LPRXOne LLC |  |  | – |  |  |  |  |
| 25-40985 | LPRXThree LLC |  |  | – |  |  |  |  |
| 25-40986 | LPRXTwo LLC |  |  | – |  |  |  |  |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 5** |
| **In re: 23andMe Inc.** | Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 3/24/2025 - 3/31/2025 |
| **Postpetition Liabilities Aging** | **Postpetition Liabilities Aging** | **Postpetition Liabilities Aging** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Day Past Due** | **Day Past Due** | **Day Past Due** | **Day Past Due** | **Day Past Due** |  |
|  | **Current** | **1 - 30** | **31 - 60** | **61 - 90** | **91+** | **Total** |
|  Accounts payable and accrued expenses | 784 |  |  |  |  | **784** |
|  Deferred revenue |  |  |  |  |  | **—** |
|  Lease Liabilities |  |  |  |  |  | **—** |
|  Other Current Liabilities |  |  |  |  |  | **—** |
|  Other Liabilities |  |  |  |  |  | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total postpetition liabilities** | **784** |  |  |  |  | **784** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 6** |
| **In re: 23andMe Inc.** | Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 3/24/2025 - 3/31/2025 |
| **Payments to Insiders** | **Payments to Insiders** | **Payments to Insiders** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Case No.** | **Entity** | **Recipient** | **Total Payments** |
| 25-40977 | 23andMe Inc. | Officer#1 | $26 |
| 25-40977 | 23andMe Inc. | Officer#2 | $19 |
| 25-40977 | 23andMe Inc. | Director#1 | $2 |
|  |  | **Total** | $**47** |

---

**<u>Notes:</u>** 

With respect to insiders, all cash payments made were on account of ordinary course salaries and benefits.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 7** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 3/24/2025 - 3/31/2025 |
| **Certification Regarding Postpetition Taxes** | **Certification Regarding Postpetition Taxes** | **Certification Regarding Postpetition Taxes** |

---

The Debtors hereby submit this attestation regarding postpetition tax payments during the period of March 24 through March 31, 2025.

The Debtors are authorized to pay Taxes and Fees that arise or accrue in the ordinary course of business on a postpetition basis consistent with prepetition practices. The Debtors believe that they are current with respect to any postpetition Taxes and Fees that have come due.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 4/30/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 4/30/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 8** |
| **In re: 23andMe Inc.** | Case No.: | 25-40977 |
|  | Reporting Period: | 3/24/2025 - 3/31/2025 |
| **Schedule of Pre-Petition Payments** | **Schedule of Pre-Petition Payments** | **Schedule of Pre-Petition Payments** |

---

The Debtors hereby submit this attestation regarding prepetition payments during the period of March 24 through March 31, 2025

All payments made by the Debtors during the period of March 24 through March 31, 2025 (and included in the disbursements reported herein), were authorized under First Day Orders granted by the Court.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 4/30/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 4/30/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 9** |
| **In re: 23andMe Inc.** | Case No.: | 25-40977 |
|  | Reporting Period: | 3/24/2025 - 3/31/2025 |
| **Schedule of Payments to Insiders** | **Schedule of Payments to Insiders** | **Schedule of Payments to Insiders** |

---

The Debtors hereby submit this attestation regarding prepetition payments during the period of March 24 through March 31, 2025

With respect to insiders, all cash payments made were on account of ordinary course salaries and benefits.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 4/30/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 4/30/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 10** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 3/24/2025 - 3/31/2025 |
| **All Bank Statements and Bank Reconciliations for the Reporting Period** | **All Bank Statements and Bank Reconciliations for the Reporting Period** | **All Bank Statements and Bank Reconciliations for the Reporting Period** |

---

The Debtors hereby submit this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and journal entries.

The Debtors' standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting period. I attest that each of the Debtors' bank accounts has been reconciled in accordance with their standard practices.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 4/30/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 4/30/2025 |
| Printed Name of Authorized Individual | Date |

---

## Exhibit 99.2

**Exhibit 99.2** 

**UNITED STATES BANKRUPTCY COURT** 

**EASTERN DISTRICT OF MISSOURI** 

**EASTERN DIVISION** 

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;In re: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chapter 11 |
| &nbsp;&nbsp;&nbsp;23ANDME HOLDING CO., *et al.*,<sup>1</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Case No. 25-40976-357 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debtors. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Jointly Administered) |

---

**GLOBAL NOTES AND STATEMENTS OF LIMITATIONS, METHODOLOGY,** 

**AND DISCLAIMERS REGARDING THE DEBTORS' MONTHLY OPERATING REPORT** 

On March 23, 2025 (the "<u>Petition Date</u>"), the above-captioned debtors and debtors in possession (collectively, the "<u>Debtors</u>") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "<u>Bankruptcy Code</u>") in the United States Bankruptcy Court for the Eastern District of Missouri (the "<u>Court</u>"), thereby commencing these chapter 11 cases. The Debtors are operating their business and managing their property as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. On March 27, 2025, the Court entered an order authorizing the joint administration of these chapter 11 cases pursuant to rule 1015(b) of the Federal Rules of Bankruptcy Procedure [Docket No. 105]. On April 3, 2025, the United States Trustee for the Eastern District of Missouri appointed an official committee of unsecured creditors pursuant to section 1102(a)(1) of the Bankruptcy Code (the "<u>Committee</u>") [Docket No. 159].

The following global notes and statements of limitations, methodology, and disclaimers should be referred to and referenced in connection with any review of this MOR (as defined below).

**1.** **General Methodology.** The Debtors are filing this consolidated monthly operating report
(" <u>MOR</u> ") for the period from April 1, 2025, through and including April 30, 2025 (the " <u>Reporting Period</u> "), solely for the purpose of complying with the monthly reporting requirements applicable in the
Debtors' chapter 11 cases. This MOR is (a) unaudited, has not been prepared in accordance with (i) Generally Accepted Accounting Principles in the United States (" <u>U.S. GAAP</u> ") and does not include all of the
information and footnotes required by U.S. GAAP, or (ii) federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any period reporting requirements thereunder
and (b) remains subject to future adjustments. This MOR is not intended to reconcile any financial statements otherwise prepared or distributed by the Debtors. This MOR should not be relied upon by any person for information relating to the
current or future financial condition of the Debtors or their affiliates, the occurrence or non-occurrence of any event, or the performance of any of the

<sup>1</sup> The Debtors in each of these cases, along with the last four digits of each Debtor's federal tax identification number, are: 23andMe Holding Co. (0344), 23andMe, Inc. (7371), 23andMe Pharmacy Holdings, Inc. (4690), Lemonaid Community Pharmacy, Inc. (7330), Lemonaid Health, Inc. (6739), Lemonaid Pharmacy Holdings Inc. (6500), LPharm CS LLC (1125), LPharm INS LLC (9800), LPharm RX LLC (7746), LPRXOne LLC (3447), LPRXThree LLC (3852), and LPRXTwo LLC (1595). The Debtors' service address for purposes of these chapter 11 cases is: 870 Market Street, Room 415, San Francisco, CA 94102. 

------

Debtors or their affiliates as the results of operations addressed herein are not necessarily indicative of results that may be expected from any other period or for the full year and may not reflect the combined results of the Debtors' operations, the Debtors' financial position, or the Debtors' schedule of receipts and disbursements in the future. The preparation of this MOR required the Debtors to make commercially reasonable estimates and assumptions with respect to the reported amounts of assets and liabilities at month end and the reported amounts of revenues and expenses during the applicable reporting periods. Actual results could differ materially from such estimates.

**2.** **Basis of Presentation.** In preparing this MOR, the Debtors relied on financial information from the books
and records available to them at the time of such preparation. The financial information contained herein is derived from the Debtors' books and records without, among other things, all adjustments or reclassifications that may be necessary or
typical for consolidated financial statements or to accord with U.S. GAAP. As a result, all information contained herein is subject to change, which could be material. Although the Debtors made commercially reasonable efforts to ensure the material
accuracy and completeness of this MOR and because the Debtors' accounting systems were developed to produce consolidated financial statements by business unit rather than financial statements by legal entity, it is possible that not all
assets, liabilities, income, or expenses have been attributed to the correct legal entity.

The information contained in this MOR has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtors believe that the financial information presented in this MOR could be subject to material change.

For the reasons discussed above, there can be no assurance that the financial information presented herein is complete, and readers are strongly cautioned not to place undue reliance on this MOR. Moreover, the results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the results of operations, financial position and cash flows of the Debtors in the future.

**3.** **Reporting Period.** Unless otherwise noted herein, this MOR generally reflects the Debtors' books
and records for the applicable Reporting Period. Unless otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

**4.** **Consolidated Entity Accounts Payable and Disbursement Systems.** Receivables and payables among the
Debtors and their non-Debtor affiliates<sup>2</sup> are reported per the Debtors' unaudited books and records. As described more fully in the *Final Order (I) Authorizing (A) Continued Use of Cash Management System, (B) Maintenance of Bank Accounts and Business Forms, (C) Performance of Intercompany Transactions, And (D) Certain Prepetition Obligations to Be Honored; (II) Granting Administrative Expense Priority Status to Postpetition Intercompany Claims Against The Debtors; And (III) Granting Related Relief* [Docket No. 297], the Debtors utilize an integrated, centralized cash management system in the ordinary course of business to collect, concentrate, and disburse funds generated from their operations. Cash is being received and
disbursed by the Debtors during these chapter 11 cases in a manner consistent with the Debtors' historical cash management practices. **  

**5.** **Accuracy.** The financial information disclosed herein was not prepared in accordance with federal or
state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling, or
transferring claims against or interests in the Debtors should evaluate this financial information in light

<sup>2</sup> Non-Debtor affiliates exclude any controlling shareholder of 23andMe Holding Co.

------

of the purposes for which it was prepared. The Debtors and their advisors are not liable for and undertake no responsibility (i) to indicate variations from state, federal, or other securities laws or (ii) for any evaluations of the Debtors, including of their financial condition, based on the information provided in this MOR or any other information.

**6.** **Debtor in Possession Financing.** On April 23, 2025, the Court entered the *Final Order (A) Authorizing the Debtors to Obtain Postpetition Financing, Grant Liens, Provide Superpriority Administrative Expense Claims and Use Cash Collateral, (B) Modifying the Automatic Stay, and (C) Granting Related Relief* [Docket No. 313] (the " <u>DIP Order</u> "), authorizing the Debtors, jointly and severally, to obtain a non-amortizing, priming, super-priority senior secured postpetition
credit facility (the " <u>DIP Facility</u> ") in an aggregate principal amount of up to $35,000,000 of which (a) up to $10 million became available following entry of the DIP Order and (b) the remaining $25 million
became available on May 16, 2025, following the Debtors' announcement of an Acceptable Successful Bid (as defined in the DIP Credit Agreement (as defined below)), in each case, subject to the terms and conditions set forth in DIP Order
and that certain *Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement* by and among the Debtors, as Borrowers, and JMB Capital
Partners Lending, LLC (the "DIP Lender") or its permitted designees or assignees, as Lender (as amended, modified, or supplemented from time to time, the "DIP Credit Agreement"). The Debtors did not borrow any amounts under
the DIP Facility in the Reporting Period.

Please refer to the DIP Order for additional details.

**7.** **Payment of Prepetition Claims Pursuant to First Day Orders.** Following the Petition Date, the Court
entered various orders authorizing, but not directing, the Debtors to, among other things, pay certain prepetition: (a) charges assessed by the Debtors' banks; (b) insurance obligations; (c) employee wages, salaries, and related
items (including employee benefit programs); (d) taxes and assessments; (e) customer program obligations; and (f) critical vendor obligations (collectively, the " <u>First Day Orders</u> "). To the extent any payments were made
during the Reporting Period on account of prepetition claims pursuant to the authority granted to the Debtors by the Court under the First Day Orders, such payments have been included in this MOR (subject to the notes and statements and limitations
provided herein).

**8.** **Reservation of Rights.** The Debtors reserve all rights to amend or supplement this MOR in all respects,
as may be necessary or appropriate. Nothing contained in this MOR shall constitute a waiver of any of the Debtors' rights or an admission with respect to their chapter 11 cases.

**9.** **Insiders.** Information regarding the individuals listed as "insiders" in this MOR have been
included for informational purposes only. The Debtors do not take any position with respect to, and reserve all rights with respect to: (a) such person's influence over or control of the Debtors, (b) the management responsibilities
or functions of such individual, (c) the decision-making or corporate authority of such individual, and (d) whether such individual could successfully argue that he or she is not an "insider" under applicable law, including any
state, federal, or other securities law, or with respect to any theories of liability or for any other purpose.

**10.** **Currency.** All amounts shown in this MOR are in United States dollars unless otherwise stated.

**11.** **MOR Information Requests.** The Debtors and/or their advisors are managing an email address to which
parties may send requests for additional information from the Debtors regarding the information contained in this and all other MORs. For any such requests, please send an email to <u>23andMeInfo@ra.kroll.com.</u> 

------

**12.** **Specific MOR Disclosures.** 

**Notes to Part 1: Cash Receipts and Disbursements** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Figures include cash as reported in the Debtors' bank statements. Reconciliation differences will exist
between bank statement balances and balance sheet cash balances due to ordinary course timing differences between payment execution in the Debtors' financial system and disbursement of funds from Debtor bank accounts.

**Notes to Part 2: Asset and Liability Status** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• See "Basis of Presentation" notes above regarding certain adjustments or reclassifications applied at
a consolidated level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Because the Debtors' existing recording systems were not designed to distinguish between pre- and postpetition liabilities, the Debtors have commenced a process to distinguish between pre- and postpetition liabilities, the results of which are reflected in this
MOR. As the Debtors continue this process and additional information becomes available, the allocation of liabilities between prepetition and postpetition periods may change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Items (k–m)</u>: Prepetition liabilities (*i.e.*, items (k), (l), and (m)) reflect liabilities
included in "Liabilities subject to compromise" on the Debtors' balance sheet as well as other prepetition liabilities that may be uncompromised pursuant to the relief granted via the First Day Orders. The Debtors' inclusion
or exclusion of any amounts in the presentation of "liabilities subject to compromise" in the Balance Sheet is done solely to enable the Debtors to expeditiously prepare this MOR pursuant to the Debtors' reporting obligations and
does not indicate a view, of the Debtors or of any other person, as to whether and to what extent the respective liabilities may be impaired.

**Notes to Part 4: Income Statement** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• See "Basis of Presentation" notes above regarding certain adjustments or reclassifications applied at
a consolidated level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This MOR has not been subject to certain quarterly or annual adjustment procedures, including income tax
provision and impairment assessment procedures. The information presented herein may materially differ if such procedures were applied.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (b)</u>: "Cost of revenue" on the Debtors' balance sheet is classified as a cost of
goods sold (*i.e.*, item (b)). Cost of Revenue includes the day-to-day costs of operating the business like facility and equipment costs, and depreciation and
amortization.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (e)</u>: Depreciation and Amortization are netted with the totals for the Cost of Service, General and
Administrative and Other expenses and have not been broken out as a separate line item.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (f)</u>: Other expenses (*i.e.*, item (f)) include Research and Development expenses and other
income.

------

**Notes to Part 5: Professional Fees and Expenses** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors did not make any payments to any restructuring professionals or any professionals of the Committee
during this Reporting Period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (c)</u>: Part 5(c) provides the total of professional fees and expenses paid presented in Part 5(a) and
Part 5(b), as well as professional fees and expenses paid for professionals employed by the Committee.

**Notes to Part 6: Postpetition Taxes** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the ordinary course of business, the Debtors collect, withhold, and incur income taxes, franchise taxes, sales
and use taxes, personal property taxes, foreign taxes, and other governmental and regulatory taxes, penalties, interests, assessments, and fees.

**Notes to Part 7: Questionnaire** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (a)</u>: Pursuant to the relief granted in the Debtors' various First Day Orders, the Debtors have
made payments on account of prepetition debts as they come due in the ordinary course of business. Where applicable, details of these payments have been delivered to the required notice parties pursuant to the reporting requirements set forth in the
First Day Orders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (g)</u>: Please refer to the "Debtor in Possession Financing" notes above regarding approved
postpetition financing.

------

![LOGO](g847630dsp038.jpg)

UNITED STATES BANKRUPTCY COURT Eastern DISTRICT OF Missouri In Re. 23andMe, Inc. § Case No. 25-40977 § § Lead Case No. 25-40976 Debtor(s) Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 04/30/2025 Petition Date: 03/23/2025 Months Pending: 1 Industry Classification: 6 2 1 5 Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Employees (current): 247 Debtor's Full-Time Employees (as of date of order for relief): 262 Supporting Documentation (check all that are attached): (For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement) Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Thomas H. Riske Thomas H. Riske Signature of Responsible Party Printed Name of Responsible Party 05/30/2025 120 S. Central Avenue, Suite 1800, St. Louis, Missouri Date 63105 Address STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R.

UST Form 11-MOR (12/01/2021) 1

------

![LOGO](g847630dsp039.jpg)

Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $52,215,164 b. Total receipts (net of transfers between accounts) $9,236,899 $11,440,642 c. Total disbursements (net of transfers between accounts) $15,771,320 $17,809,881 d. Cash balance end of month (a+b-c) $45,680,743 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation (c+e) $15,771,320 $17,809,881 Part 2: Asset and Liability Status Current Month (Not generally applicable to Individual Debtors. See Instructions.) a. Accounts receivable (total net of allowance) $591,753 b. Accounts receivable over 90 days outstanding (net of allowance) $0 c. Inventory (Book Market Other (attach explanation)) $14,530,218 d Total current assets $69,154,725 e. Total assets $147,561,311 f. Postpetition payables (excluding taxes) $15,378,841 g. Postpetition payables past due (excluding taxes) $1,130,997 h. Postpetition taxes payable $88,780 i. Postpetition taxes past due $0 j. Total postpetition debt (f+h) $15,467,621 k. Prepetition secured debt $224,364 l. Prepetition priority debt $200,188 m. Prepetition unsecured debt $138,421,833 n. Total liabilities (debt) (j+k+l+m) $154,314,005 o. Ending equity/net worth (e-n) $-6,752,695 Part 3: Assets Sold or Transferred Current Month Cumulative a. Total cash sales price for assets sold/transferred outside the ordinary $0 $0 course of business b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business $0 $0 c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $0 $0 Part 4: Income Statement (Statement of Operations) Current Month Cumulative (Not generally applicable to Individual Debtors. See Instructions.) a. Gross income/sales (net of returns and allowances) $8,317,060 b. Cost of goods sold (inclusive of depreciation, if applicable) $3,327,372 c. Gross profit (a-b) $4,989,687 d. Selling expenses $2,264,834 e. General and administrative expenses $4,865,356 f. Other expenses $4,794,192 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $-110,529 i. Taxes (local, state, and federal) $0 j. Reorganization items $-26,996,316 k. Profit $20,172,150 $-108,890

UST Form 11-MOR (12/01/2021) 2

------

![LOGO](g847630dsp040.jpg)

Part 5: Professional Fees and Expenses Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative a. Debtor's professional fees & expenses (bankruptcy) Aggregate Total $0 $0 $0 $0 Itemized Breakdown by Firm Firm Name Role i Alvarez & Marsal North Ameri Financial Professional $0 $0 $0 $0 ii Carmody MacDonald P.C. Local Counsel $0 $0 $0 $0 iii Goodwin Procter LLP Special Counsel $0 $0 $0 $0 iv Kroll Restructuring AdministratOther $0 $0 $0 $0 v Lewis Rice LLC Special Counsel $0 $0 $0 $0 vi Moelis & Company, LLC Financial Professional $0 $0 $0 $0 vii Paul, Weiss, Rifkind, Wharton &Lead Counsel $0 $0 $0 $0 viii ix x xi xii xiii xiv xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi

UST Form 11-MOR (12/01/2021) 3

------

![LOGO](g847630dsp041.jpg)

xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii

UST Form 11-MOR (12/01/2021) 4

------

![LOGO](g847630dsp042.jpg)

lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative b. Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total $0 $0 $0 $0 Itemized Breakdown by Firm Firm Name Role i BDO USA LLP Other $0 $0 $0 $0 ii Captiva Advisory, Inc. Other $0 $0 $0 $0 iii Deloitte & Touche LLP Other $0 $0 $0 $0 iv Duane Morris LLP Other $0 $0 $0 $0 v FisherBroyles, LLP Other $0 $0 $0 $0 vi Foley & Lardner LLP Other $0 $0 $0 $0 vii Frank, Rimerman Co LLP Other $0 $0 $0 $0 viii Gibson, Dunn & Crutcher LLP Other $0 $0 $0 $0 ix Greenberg Traurig LLP Other $0 $0 $0 $0 x Hintze Law PLLC Other $0 $0 $0 $0 xi KPMG LLP Other $0 $0 $0 $0 xii McDonnell Boehnen Hulbert & Other $0 $0 $0 $0 LLP xiii Morgan, Lewis & Bockius LLP Other $0 $0 $0 $0 xiv Osler -Hoskin & Harcourt LLP Other $0 $0 $0 $0

UST Form 11-MOR (12/01/2021) 5

------

![LOGO](g847630dsp043.jpg)

xv Quarles & Brady LLP Other $0 $0 $0 $0 xvi Reevemark, LLC Other $0 $0 $0 $0 xvii Ryan, LLC Other $0 $0 $0 $0 xviii Scale Strategy Operations LLC Other $0 $0 $0 $0 xix Sheppard Mullin Other $0 $0 $0 $0 xx Wilson Sonsini Goodrich & Ro Other $0 $0 $0 $0 xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi

UST Form 11-MOR (12/01/2021) 6

------

![LOGO](g847630dsp044.jpg)

lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii

UST Form 11-MOR (12/01/2021) 7

------

![LOGO](g847630dsp045.jpg)

xcix c c. All professional fees and expenses (debtor & committees) $0 $0 $0 $0 Part 6: Postpetition Taxes Current Month Cumulative a. Postpetition income taxes accrued (local, state, and federal) $0 $0 b. Postpetition income taxes paid (local, state, and federal) $0 $0 c. Postpetition employer payroll taxes accrued $52,922 $103,758 d. Postpetition employer payroll taxes paid $352,407 $440,761 e. Postpetition property taxes paid $0 $0 f. Postpetition other taxes accrued (local, state, and federal) $35,858 $54,648 g. Postpetition other taxes paid (local, state, and federal) $5,271 $5,271 Part 7: Questionnaire—During this reporting period: a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No b. Were any payments made outside the ordinary course of business Yes No without court approval? (if yes, see Instructions) c. Were any payments made to or on behalf of insiders? Yes No d. Are you current on postpetition tax return filings? Yes No e. Are you current on postpetition estimated tax payments? Yes No f. Were all trust fund taxes remitted on a current basis? Yes No g. Was there any postpetition borrowing, other than trade credit? Yes No (if yes, see Instructions) h. Were all payments made to or on behalf of professionals approved by Yes No N/A the court? i. Do you have: Worker's compensation insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) General liability insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) j. Has a plan of reorganization been filed with the court? Yes No k. Has a disclosure statement been filed with the court? Yes No l. Are you current with quarterly U.S. Trustee fees as Yes No set forth under 28 U.S.C. § 1930?

UST Form 11-MOR (12/01/2021) 8

------

![LOGO](g847630dsp046.jpg)

Part 8: Individual Chapter 11 Debtors (Only) a. Gross income (receipts) from salary and wages $0 b. Gross income (receipts) from self-employment $0 c. Gross income from all other sources $0 d. Total income in the reporting period (a+b+c) $0 e. Payroll deductions $0 f. Self-employment related expenses $0 g. Living expenses $0 h. All other expenses $0 i. Total expenses in the reporting period (e+f+g+h) $0 j. Difference between total income and total expenses (d-i) $0 k. List the total amount of all postpetition debts that are past due $0 l. Are you required to pay any Domestic Support Obligations as defined by 11 Yes No U.S.C § 101(14A)? m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A Privacy Act Statement 28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F). I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate. /s/ Joe Selsavage Joe Selsavage Signature of Responsible Party Printed Name of Responsible Party Interim Chief Executive Officer and Chief Financial and 05/30/2025 Title Date

UST Form 11-MOR (12/01/2021) 9

------

![LOGO](g847630dsp047.jpg)

PageTwoPartTwo

UST Form 11-MOR (12/01/2021) 10

------

![LOGO](g847630dsp048.jpg)

PageTwoPartTwo

UST Form 11-MOR (12/01/2021) 11

------

![LOGO](g847630dsp049.jpg)

UST Form 11-MOR (12/01/2021) 12

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 1** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 4/1/2025 - 4/30/2025 |
| **Cash Receipts and Disbursements** | **Cash Receipts and Disbursements** | **Cash Receipts and Disbursements** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **25-40977<br>23andMe,<br>Inc.** | **25-40976<br>23andMe<br>Holding Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings<br>Inc.** | **25-40982<br>LPharm<br>CS LLC** | **25-40983<br>LPharm<br>INS<br>LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40975<br>LPRXOne<br>LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  Beginning bank cash balance | $52215 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total receipts | 9237 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total disbursements | (15771) |  |  |  |  |  |  |  |  |  |  |  |
|  **Ending bank cash balance** | $**45681** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

**Notes**: Cash Balance includes approximately $7.6M of Professional Fee Admin Reserves in the Carve Out Account.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 2** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 4/1/2025 - 4/30/2025 |
| **Balance Sheet** | **Balance Sheet** | **Balance Sheet** |

---

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Consolidated** | **25-40977<br>23andMe,<br>Inc.** | **25-40975<br>LPRXOne<br>LLC** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40976<br>23andMe<br>Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings<br>Inc.** | **25-40982<br>LPharm<br>CS LLC** | **25-40983<br>LPharm<br>INS<br>LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  **Assets** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **Current assets:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Cash and Cash Equivalents | $34950 | $34950 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Accounts receivable | 592 | 592 |  |  |  |  |  |  |  |  |  |  |  |
|  Prepaid Expenses | 19127 | 19083 |  | 44 |  |  |  |  |  |  |  |  |  |
|  Inventory | 14746 | 14530 | 216 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current assets** | **69415** | **69155** | **216** | **44** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Property and equipment, net | $1147 | $937 | $209 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Lease right-of-use assets, net | 506 | 390 | 116 |  |  |  |  |  |  |  |  |  |  |
|  Restricted cash | 10731 | 10731 |  |  |  |  |  |  |  |  |  |  |  |
|  Intangible assets, net | 43459 | 41744 |  | 1714 |  |  |  |  |  |  |  |  |  |
|  Other assets | 24758 | 24603 | 155 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total assets** | $**150016** | $**147561** | $**696** | $**1758** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |
|  **Liabilities** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **Current liabilities:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Accounts payable and accrued expenses | $25790 | $24764 | $430 | $596 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Deferred revenue | 44477 | 43693 | 439 | 345 |  |  |  |  |  |  |  |  |  |
|  Lease Liabilities | 6878 | 6878 |  |  |  |  |  |  |  |  |  |  |  |
|  Tax Payable | 200 | 200 |  |  |  |  |  |  |  |  |  |  |  |
|  Other Current Liabilities | 1361 | 1361 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current liabilities** | **78707** | **76896** | **869** | **941** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Other Liabilities | 224 | 224 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total liabilities not subject to compromise** | **78931** | **77121** | **869** | **941** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Liabilities subject to compromise:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Accounts payable and accrued payable | $12887 | $12759 | $69 | $60 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Lease liabilities | 26936 | 26826 | 110 |  |  |  |  |  |  |  |  |  |  |
|  Loss contingencies | 37520 | 37520 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total liabilities** | **156274** | **154225** | **1048** | **1001** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Common Stock | $3 | $3 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Additional paid-in capital | 2427228 | 2427228 |  |  |  |  |  |  |  |  |  |  |  |
|  Accumulated Deficit - Retained Earnings | (67064) | (67064) |  |  |  |  |  |  |  |  |  |  |  |
|  Accumulated Deficit - Net Income | (2366425) | (2366425) |  |  |  |  |  |  |  |  |  |  |  |
|  **Total liabilities and equity** | $**150016** | $**147967** | $**1048** | $**1001** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

**Notes**: The Debtors maintain their books and records on a consolidated basis in the ordinary course of business, however, this MOR was prepared on an entity-by-entity basis. Accordingly, column "Consolidated" was included to provide a consolidated view of the Balance Sheet for reconciliation purposes only.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 3** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 4/1/2025 - 4/30/2025 |
| **Income Statement** | **Income Statement** | **Income Statement** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **25-40977<br>23andMe,<br>Inc.** | **25-40975<br>LPRXOne<br>LLC** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40976<br>23andMe<br>Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings<br>Inc.** | **25-40982<br>LPharm<br>CS LLC** | **25-40983<br>LPharm<br>INS<br>LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  **Revenue:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Total consumer services revenue | $8202 | $— | $290 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total research services and other revenue | 115 |  |  |  |  |  |  |  |  |  |  |  |
|  Total product revenue |  | 1639 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total revenue** | **8317** | **1639** | **290** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Expenses:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Cost of revenue | $3327 | $775 | $843 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Sales and marketing | 2265 |  |  |  |  |  |  |  |  |  |  |  |
|  General and administrative | 4865 |  |  |  |  |  |  |  |  |  |  |  |
|  Research and development | 4785 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total expenses** | **15242** | **775** | **843** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Income (Loss) from operations | $(6925) | $864 | $(553) | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  **Interest and other (expense) income:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Total - Interest income | $111 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total - Other (expense) income | (9) |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total interest and other (expense) income** | **101** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Reorganization items** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Professional fees | $130 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Board fees | $(2207) |  |  |  |  |  |  |  |  |  |  |  |
|  Legal fees | $(6214) |  |  |  |  |  |  |  |  |  |  |  |
|  Gain/Loss on Sale of Subsidiary | $35287 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total Reorganization item gain (losses)** | **26996** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Net Loss | $20172 | $864 | $(553) | $— | $— | $— | $— | $— | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Net income (loss)** | $**20172** | $**864** | $**(553)** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 4** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 4/1/2025 - 4/30/2025 |
| **Accounts Receivable Aging** | **Accounts Receivable Aging** | **Accounts Receivable Aging** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Current -31** | **32 -61** | **62 -91** | **92+** | **Gross AR** | **Allowance for<br>Doubtful<br>Accounts** | **Net AR** |
| 25-40977 | 23andMe, Inc. | $566 | $24 | $2 | $500 | $1092 | $500 | $592 |
| 25-40976 | 23andMe Holding Co. |  |  |  |  |  |  |  |
| 25-40978 | 23andMe Pharmacy Holdings, Inc. |  |  |  |  |  |  |  |
| 25-40979 | Lemonaid Community Pharmacy, Inc |  |  |  |  |  |  |  |
| 25-40980 | Lemonaid Health, Inc. |  |  |  |  |  |  |  |
| 25-40981 | Lemonaid Pharmacy Holdings Inc. |  |  |  |  |  |  |  |
| 25-40982 | LPharm CS LLC |  |  |  |  |  |  |  |
| 25-40983 | LPharm INS LLC |  |  |  |  |  |  |  |
| 25-40984 | LPharm RX LLC |  |  |  |  |  |  |  |
| 25-40975 | LPRXOne LLC |  |  |  |  |  |  |  |
| 25-40985 | LPRXThree LLC |  |  |  |  |  |  |  |
| 25-40986 | LPRXTwo LLC |  |  |  |  |  |  |  |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 5** |
| **In re: 23andMe Inc.** | Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 4/1/2025 - 4/30/2025 |
| **Postpetition Liabilities Aging** | **Postpetition Liabilities Aging** | **Postpetition Liabilities Aging** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Day Past Due** | **Day Past Due** | **Day Past Due** | **Day Past Due** | **Day Past Due** | |
|  | **Current** | **1 -30** | **31 -60** | **61 -90** | **91+** |<br>**Total** |
|  Accounts payable and accrued expenses | 14280 | 902 | 174 | 22 |  | 15379 |
|  Deferred revenue |  |  |  |  |  |  |
|  Lease Liabilities |  |  |  |  |  |  |
|  Other Current Liabilities |  |  |  |  |  |  |
|  Other Liabilities |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total postpetition liabilities** | **14280** | **902** | **174** | **22** |  | **15379** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 6** |
| **In re: 23andMe Inc.** | Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 4/1/2025 - 4/30/2025 |
| **Payments to Insiders** | **Payments to Insiders** | **Payments to Insiders** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Case No.** | **Entity** | **Recipient** | **Total Payments** |
| 25-40977 | 23andMe Inc. | Officer #1 | $52 |
| 25-40977 | 23andMe Inc. | Officer #2 | $40 |
| 25-40977 | 23andMe Inc. | Director #2 | $20 |
| 25-40977 | 23andMe Inc. | Director #3 | $20 |
| 25-40977 | 23andMe Inc. | Director #4 | $20 |
|  |  | **Total** | $**153** |

---

**<u>Notes:</u>**

With respect to insiders, all cash payments made were on account of ordinary course salaries and/or fees, benefits, authorized travel, and and expense reimbursements.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 7** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 4/1/2025 - 4/30/2025 |
| **Certification Regarding Postpetition Taxes** | **Certification Regarding Postpetition Taxes** | **Certification Regarding Postpetition Taxes** |

---

The Debtors hereby submit this attestation regarding postpetition tax payments during the period of April 1 through April 30, 2025.

The Debtors are authorized to pay Taxes and Fees that arise or accrue in the ordinary course of business on a postpetition basis consistent with prepetition practices. The Debtors believe that they are current with respect to any postpetition Taxes and Fees that have come due.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 5/30/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 5/30/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 8** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 4/1/2025 - 4/30/2025 |
| **Schedule of Pre-Petition Payments** | **Schedule of Pre-Petition Payments** | **Schedule of Pre-Petition Payments** |

---

The Debtors hereby submit this attestation regarding prepetition payments during the period of April 1 through April 30, 2025

All payments made by the Debtors during the period of April 1 through April 30, 2025 (and included in the disbursements reported herein), were authorized under First Day Orders granted by the Court.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 5/30/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 5/30/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 9** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 4/1/2025 - 4/30/2025 |
| **Schedule of Payments to Insiders** | **Schedule of Payments to Insiders** | **Schedule of Payments to Insiders** |

---

The Debtors hereby submit this attestation regarding prepetition payments during the period of April 1 through April 30, 2025

With respect to insiders, all cash payments made were on account of ordinary course salaries and/or fees, benefits, authorized travel and expense reimbursements.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 5/30/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 5/30/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 10** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 4/1/2025 - 4/30/2025 |
| **All Bank Statements and Bank Reconciliations for the Reporting Period** | **All Bank Statements and Bank Reconciliations for the Reporting Period** | **All Bank Statements and Bank Reconciliations for the Reporting Period** |

---

The Debtors hereby submit this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and journal entries.

The Debtors' standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting period. I attest that each of the Debtors' bank accounts has been reconciled in accordance with their standard practices.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 5/30/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 5/30/2025 |
| Printed Name of Authorized Individual | Date |

---

## Exhibit 99.3

**Exhibit 99.3** 

**UNITED STATES BANKRUPTCY COURT** 

**EASTERN DISTRICT OF MISSOURI** 

**EASTERN DIVISION** 

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;In re: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chapter 11 |
| &nbsp;&nbsp;&nbsp;23ANDME HOLDING CO., *et al.*,<sup>1</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Case No. 25-40976-357 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debtors. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Jointly Administered) |

---

**GLOBAL NOTES AND STATEMENTS OF LIMITATIONS, METHODOLOGY,** 

**AND DISCLAIMERS REGARDING THE DEBTORS' MONTHLY OPERATING REPORT** 

On March 23, 2025 (the "<u>Petition Date</u>"), the above-captioned debtors and debtors in possession (collectively, the "<u>Debtors</u>") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "<u>Bankruptcy Code</u>") in the United States Bankruptcy Court for the Eastern District of Missouri (the "<u>Court</u>"), thereby commencing these chapter 11 cases. The Debtors are operating their business and managing their property as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. On March 27, 2025, the Court entered an order authorizing the joint administration of these chapter 11 cases pursuant to rule 1015(b) of the Federal Rules of Bankruptcy Procedure [Docket No. 105]. On April 3, 2025, the United States Trustee for the Eastern District of Missouri appointed an official committee of unsecured creditors pursuant to section 1102(a)(1) of the Bankruptcy Code (the "<u>Committee</u>") [Docket No. 159]. On June 25, 2025, the Debtors, the Committee, and certain unaffiliated holders of the Debtors' common stock filed the *Stipulation and Agreed Order By and Among the Debtors, the Official Committee of Unsecured Creditors, and Certain Equity Holders Resolving Requests for the Appointment of an Official Committee of Equity Holder*s (the "<u>Equity Committee Stipulation</u>") [Docket No. 891] agreeing to support the appointment of an official committee of equity security holders on the terms set forth in the Equity Committee Stipulation.

The following global notes and statements of limitations, methodology, and disclaimers should be referred to and referenced in connection with any review of this MOR (as defined below).

**1.** **General Methodology.** The Debtors are filing this consolidated monthly operating report
("MOR") for the period from May 1, 2025, through and including May 31, 2025 (the " <u>Reporting Period</u> "), solely for the purpose of complying with the monthly reporting requirements applicable in the
Debtors' chapter 11 cases. This MOR is (a) unaudited, has not been prepared in accordance with (i) Generally Accepted Accounting Principles in the United States (" <u>U.S. GAAP</u> ") and does not include all of the
information and footnotes required by U.S. GAAP, or (ii) federal or state securities laws or other

<sup>1</sup> The Debtors in each of these cases, along with the last four digits of each Debtor's federal tax identification number, are: 23andMe Holding Co. (0344), 23andMe, Inc. (7371), 23andMe Pharmacy Holdings, Inc. (4690), Lemonaid Community Pharmacy, Inc. (7330), Lemonaid Health, Inc. (6739), Lemonaid Pharmacy Holdings Inc. (6500), LPharm CS LLC (1125), LPharm INS LLC (9800), LPharm RX LLC (7746), LPRXOne LLC (3447), LPRXThree LLC (3852), and LPRXTwo LLC (1595). The Debtors' service address for purposes of these chapter 11 cases is: 870 Market Street, Room 415, San Francisco, CA 94102. 

------

applicable non-bankruptcy law or in lieu of complying with any period reporting requirements thereunder and (b) remains subject to future adjustments. This MOR is not intended to reconcile any financial statements otherwise prepared or distributed by the Debtors. This MOR should not be relied upon by any person for information relating to the current or future financial condition of the Debtors or their affiliates, the occurrence or non-occurrence of any event, or the performance of any of the Debtors or their affiliates as the results of operations addressed herein are not necessarily indicative of results that may be expected from any other period or for the full year and may not reflect the combined results of the Debtors' operations, the Debtors' financial position, or the Debtors' schedule of receipts and disbursements in the future. The preparation of this MOR required the Debtors to make commercially reasonable estimates and assumptions with respect to the reported amounts of assets and liabilities at month end and the reported amounts of revenues and expenses during the applicable reporting periods. Actual results could differ materially from such estimates.

**2.** **Basis of Presentation.** In preparing this MOR, the Debtors relied on financial information from the books
and records available to them at the time of such preparation. The financial information contained herein is derived from the Debtors' books and records without, among other things, all adjustments or reclassifications that may be necessary or
typical for consolidated financial statements or to accord with U.S. GAAP. As a result, all information contained herein is subject to change, which could be material. Although the Debtors made commercially reasonable efforts to ensure the material
accuracy and completeness of this MOR and because the Debtors' accounting systems were developed to produce consolidated financial statements by business unit rather than financial statements by legal entity, it is possible that not all
assets, liabilities, income, or expenses have been attributed to the correct legal entity.

The information contained in this MOR has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtors believe that the financial information presented in this MOR could be subject to material change.

For the reasons discussed above, there can be no assurance that the financial information presented herein is complete, and readers are strongly cautioned not to place undue reliance on this MOR. Moreover, the results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the results of operations, financial position and cash flows of the Debtors in the future.

**3.** **Reporting Period.** Unless otherwise noted herein, this MOR generally reflects the Debtors' books
and records for the applicable Reporting Period. Unless otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

**4.** **Consolidated Entity Accounts Payable and Disbursement Systems.** Receivables and payables among the
Debtors and their non-Debtor affiliates<sup>2</sup> are reported per the Debtors' unaudited books and records. As described more fully in the *Final Order (I) Authorizing (A) Continued Use of Cash Management System, (B) Maintenance of Bank Accounts and Business Forms, (C) Performance of Intercompany Transactions,* And (D) Certain
Prepetition Obligations to Be Honored; (II) Granting Administrative Expense Priority Status to Postpetition Intercompany Claims Against The Debtors; And *(III) Granting Related Relief* [Docket No. 297], the Debtors utilize an
integrated, centralized cash management system in the ordinary course of business to collect, concentrate, and disburse funds generated from their operations. Cash is being received and disbursed by the Debtors during these chapter 11 cases in a
manner consistent with the Debtors' historical cash management practices. **  

<sup>2</sup> Non-Debtor affiliates exclude any controlling shareholder of 23andMe Holding Co.

------

**5.** **Accuracy.** The financial information disclosed herein was not prepared in accordance with federal or
state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling, or
transferring claims against or interests in the Debtors should evaluate this financial information in light of the purposes for which it was prepared. The Debtors and their advisors are not liable for and undertake no responsibility (i) to
indicate variations from state, federal, or other securities laws or (ii) for any evaluations of the Debtors, including of their financial condition, based on the information provided in this MOR or any other information.

**6.** **Debtor in Possession Financing.** On April 23, 2025, the Court entered the *Final Order (A) Authorizing the Debtors to Obtain Postpetition Financing, Grant Liens, Provide Superpriority Administrative Expense Claims and Use Cash Collateral, (B) Modifying the Automatic Stay, and (C) Granting Related Relief* [Docket No. 313]
(the " <u>DIP Order</u> "), authorizing the Debtors, jointly and severally, to obtain a non-amortizing, priming, super-priority senior secured postpetition credit facility (the " <u>DIP Facility</u> ") in an aggregate principal amount of up to $35 million of which (a) up to $10 million became available following entry of the DIP Order and (b) the remaining $25 million became available on May 16,
2025, following the Debtors' announcement of an Acceptable Successful Bid (as defined in the DIP Credit Agreement (as defined below)), in each case, subject to the terms and conditions set forth in DIP Order and that certain *Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement* by and among the Debtors, as Borrowers, and JMB Capital Partners Lending, LLC (the
" <u>DIP Lender</u> ") or its permitted designees or assignees, as Lender (as amended, modified, or supplemented from time to time, the " <u>DIP Credit Agreement</u> "). On May 5, 2025, the Debtors made an initial draw of
$10 million under the DIP Facility.

Please refer to the DIP Order for additional details.

**7.** **Payment of Prepetition Claims Pursuant to First Day Orders.** Following the Petition Date, the Court
entered various orders authorizing, but not directing, the Debtors to, among other things, pay certain prepetition: (a) charges assessed by the Debtors' banks; (b) insurance obligations; (c) employee wages, salaries, and related
items (including employee benefit programs); (d) taxes and assessments; (e) customer program obligations; and (f) critical vendor obligations (collectively, the " <u>First Day Orders</u> "). To the extent any payments were made
during the Reporting Period on account of prepetition claims pursuant to the authority granted to the Debtors by the Court under the First Day Orders, such payments have been included in this MOR (subject to the notes and statements and limitations
provided herein).

**8.** **Reservation of Rights.** The Debtors reserve all rights to amend or supplement this MOR in all respects,
as may be necessary or appropriate. Nothing contained in this MOR shall constitute a waiver of any of the Debtors' rights or an admission with respect to their chapter 11 cases.

**9.** **Insiders.** Information regarding the individuals listed as "insiders" in this MOR have been
included for informational purposes only. The Debtors do not take any position with respect to, and reserve all rights with respect to: (a) such person's influence over or control of the Debtors, (b) the management responsibilities
or functions of such individual, (c) the decision-making or corporate authority of such individual, and (d) whether such individual could successfully argue that he or she is not an "insider" under applicable law, including any
state, federal, or other securities law, or with respect to any theories of liability or for any other purpose.

**10.** **Currency.** All amounts shown in this MOR are in United States dollars unless otherwise stated.

------

**11.** **MOR Information Requests.** The Debtors and/or their advisors are managing an email address to which
parties may send requests for additional information from the Debtors regarding the information contained in this and all other MORs. For any such requests, please send an email to <u>23andMeInfo@ra.kroll.com.</u> 

**12.** **Specific MOR Disclosures.** 

**Notes to Part 1: Cash Receipts and Disbursements** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Figures include cash as reported in the Debtors' bank statements. Reconciliation differences will exist
between bank statement balances and balance sheet cash balances due to ordinary course timing differences between payment execution in the Debtors' financial system and disbursement of funds from Debtor bank accounts.

**Notes to Part 2: Asset and Liability Status** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• See "Basis of Presentation" notes above regarding certain adjustments or reclassifications applied at
a consolidated level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Because the Debtors' existing recording systems were not designed to distinguish between pre- and postpetition liabilities, the Debtors have commenced a process to distinguish between pre- and postpetition liabilities, the results of which are reflected in this
MOR. As the Debtors continue this process and additional information becomes available, the allocation of liabilities between prepetition and postpetition periods may change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Items (k–m)</u>: Prepetition liabilities (*i.e.*, items (k), (l), and (m)) reflect liabilities
included in "Liabilities subject to compromise" on the Debtors' balance sheet as well as other prepetition liabilities that may be uncompromised pursuant to the relief granted via the First Day Orders. The Debtors' inclusion
or exclusion of any amounts in the presentation of "liabilities subject to compromise" in the Balance Sheet is done solely to enable the Debtors to expeditiously prepare this MOR pursuant to the Debtors' reporting obligations and
does not indicate a view, of the Debtors or of any other person, as to whether and to what extent the respective liabilities may be impaired.

**Notes to Part 4: Income Statement** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• See "Basis of Presentation" notes above regarding certain adjustments or reclassifications applied at
a consolidated level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This MOR has not been subject to certain quarterly or annual adjustment procedures, including income tax
provision and impairment assessment procedures. The information presented herein may materially differ if such procedures were applied.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (b)</u>: "Cost of revenue" on the Debtors' balance sheet is classified as a cost of
goods sold (*i.e.*, item (b)). Cost of Revenue includes the day-to-day costs of operating the business like facility and equipment costs, and depreciation and
amortization.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (e)</u>: Depreciation and Amortization are netted with the totals for the Cost of Service, General and
Administrative and Other expenses and have not been broken out as a separate line item.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (f)</u>: Other expenses (*i.e.*, item (f)) include Research and Development expenses and other
income.

------

**Notes to Part 5: Professional Fees and Expenses** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (c)</u>: Part 5(c) provides the total of professional fees and expenses paid presented in Part 5(a) and
Part 5(b), as well as professional fees and expenses paid for professionals employed by the Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors pay fees and expenses of Kroll Restructuring Administration LLC, as the Debtors' claims and
noticing agent, pursuant to the *Final Order Authorizing Appointment of Kroll Restructuring Administration LLC as Claims and Noticing Agent and Administrative Advisor Effective as of the Petition Date* [Docket No. 308].

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors pay fees and expenses of retained professionals in accordance with the Local Rules of Bankruptcy
Procedure for the Eastern District of Missouri.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors pay fees and expenses of ordinary course professionals in accordance with the *Order (I) Authorizing the Retention and Compensation of Certain Professionals Utilized in the Ordinary Course of Business and (II) Granting Related Relief* [Docket No. 354].

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors reimburse Alvarez & Marsal North America, LLC for its reasonable costs and expenses in
connection with the Debtors' Chief Restructuring Officer's appointment as the Foreign Representative in the Debtors' ancillary proceedings in the Supreme Court of British Columbia in Vancouver, British Columbia, pursuant to the
Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36 pursuant to the *Order (I) Authorizing Matthew Kvarda to Act as Foreign Representative; and (II) Granting Related Relief* [Docket No. 392].

**Notes to Part 6: Postpetition Taxes** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the ordinary course of business, the Debtors collect, withhold, and incur income taxes, franchise taxes, sales
and use taxes, personal property taxes, foreign taxes, and other governmental and regulatory and employee-related taxes, penalties, interests, assessments, and fees.

**Notes to Part 7: Questionnaire** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (a)</u>: Pursuant to the relief granted in the Debtors' various First Day Orders, the Debtors have
made payments on account of prepetition debts as they come due in the ordinary course of business. Where applicable, details of these payments have been delivered to the required notice parties pursuant to the reporting requirements set forth in the
First Day Orders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (g)</u>: Please refer to the "Debtor in Possession Financing" notes above regarding approved
postpetition financing.

------

![LOGO](g847630dsp065.jpg)

UNITED STATES BANKRUPTCY COURT Eastern DISTRICT OF Missouri In Re. 23andMe, Inc. § Case No. 25-40977 § § Lead Case No. 25-40976 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2025 Petition Date: 03/23/2025 Months Pending: 2 Industry Classification: 6 2 1 5 Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Employees (current): 235 Debtor's Full-Time Employees (as of date of order for relief): 262 Supporting Documentation (check all that are attached): (For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement) Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Thomas H. Riske Thomas H. Riske Signature of Responsible Party Printed Name of Responsible Party 06/30/2025 120 S. Central Avenue, Suite 1800, St. Louis, Missouri Date 63105 Address STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R.

UST Form 11-MOR (12/01/2021) 1

------

![LOGO](g847630dsp066.jpg)

Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $45,680,733 b. Total receipts (net of transfers between accounts) $16,710,334 $28,150,975 c. Total disbursements (net of transfers between accounts) $15,614,086 $33,423,966 d. Cash balance end of month (a+b-c) $46,776,981 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation (c+e) $15,614,086 $33,423,966 Part 2: Asset and Liability Status Current Month (Not generally applicable to Individual Debtors. See Instructions.) a. Accounts receivable (total net of allowance) $314,171 b. Accounts receivable over 90 days outstanding (net of allowance) $0 c. Inventory (Book Market Other (attach explanation)) $13,968,364 d Total current assets $72,845,845 e. Total assets $142,963,499 f. Postpetition payables (excluding taxes) $40,698,062 g. Postpetition payables past due (excluding taxes) $1,084,854 h. Postpetition taxes payable $125,526 i. Postpetition taxes past due $0 j. Total postpetition debt (f+h) $40,823,587 k. Prepetition secured debt $224,364 l. Prepetition priority debt $248,922 m. Prepetition unsecured debt $129,864,346 n. Total liabilities (debt) (j+k+l+m) $171,161,218 o. Ending equity/net worth (e-n) $-28,197,719 Part 3: Assets Sold or Transferred Current Month Cumulative a. Total cash sales price for assets sold/transferred outside the ordinary $0 $0 course of business b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business $0 $0 c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $0 $0 Part 4: Income Statement (Statement of Operations) Current Month Cumulative (Not generally applicable to Individual Debtors. See Instructions.) a. Gross income/sales (net of returns and allowances) $6,102,741 b. Cost of goods sold (inclusive of depreciation, if applicable) $1,823,529 c. Gross profit (a-b) $4,279,212 d. Selling expenses $1,868,256 e. General and administrative expenses $7,256,754 f. Other expenses $4,608,493 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $-27,673 i. Taxes (local, state, and federal) $0 j. Reorganization items $9,770,792 k. Profit 847630 (loss) -001 19Sep25 11:10 Page 66 $- 19,197,410 $-19,306,300

UST Form 11-MOR (12/01/2021) 2

------

![LOGO](g847630dsp067.jpg)

Part 5: Professional Fees and Expenses Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative a. Debtor's professional fees & expenses (bankruptcy) Aggregate Total $814,170 $814,170 $814,170 $814,170 Itemized Breakdown by Firm Firm Name Role i Alvarez & Marsal North Ameri Financial Professional $250,000 $250,000 $250,000 $250,000 ii Carmody MacDonald P.C. Local Counsel $0 $0 $0 $0 iii FTI Consulting, Inc. Other $0 $0 $0 $0 iv Goodwin Procter LLP Special Counsel $0 $0 $0 $0 v Kelley Drye & Warren LLP Other $0 $0 $0 $0 vi Kroll Restructuring AdministratOther $564,170 $564,170 $564,170 $564,170 vii Lewis Rice LLC Special Counsel $0 $0 $0 $0 viii Moelis & Company, LLC Financial Professional $0 $0 $0 $0 ix Paul, Weiss, Rifkind, Wharton &Lead Counsel $0 $0 $0 $0 x Stinson LLP Other $0 $0 $0 $0 xi xii xiii xiv xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi

UST Form 11-MOR (12/01/2021) 3

------

![LOGO](g847630dsp068.jpg)

xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii

UST Form 11-MOR (12/01/2021) 4

------

![LOGO](g847630dsp069.jpg)

lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative b. Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total $1,107,319 $1,107,319 $1,107,319 $1,107,319 Itemized Breakdown by Firm Firm Name Role i BDO Australia Other $323 $323 $323 $323 ii BDO USA LLP Other $0 $0 $0 $0 iii Captiva Advisory, Inc. Other $2,951 $2,951 $2,951 $2,951 iv Deloitte & Touche LLP Other $0 $0 $0 $0 v Duane Morris LLP Other $4,881 $4,881 $4,881 $4,881 vi FisherBroyles, LLP Other $0 $0 $0 $0 vii Foley & Lardner LLP Other $0 $0 $0 $0 viii Frank, Rimerman Co LLP Other $0 $0 $0 $0 ix Gibson, Dunn & Crutcher LLP Other $0 $0 $0 $0 x Greenberg Traurig LLP Other $125,000 $125,000 $125,000 $125,000 xi Hintze Law PLLC Other $0 $0 $0 $0 xii KPMG LLP Other $0 $0 $0 $0 xiii McCarthy Tétrault LLP Other $50,000 $50,000 $50,000 $50,000 xiv McDonnell Boehnen Hulbert & Other $0 $0 $0 $0 LLP

UST Form 11-MOR (12/01/2021) 5

------

![LOGO](g847630dsp070.jpg)

xv Morgan, Lewis & Bockius LLP Other $530,503 $530,503 $530,503 $530,503 xvi Osler Hoskin & Harcourt LLP Other $4,075 $4,075 $4,075 $4,075 xvii Quarles & Brady LLP Other $0 $0 $0 $0 xviii Reevemark, LLC Other $388,900 $388,900 $388,900 $388,900 xix Ryan, LLC Other $0 $0 $0 $0 xx Scale Strategy Operations LLC Other $0 $0 $0 $0 xxi Sheppard Mullin Other $686 $686 $686 $686 xxii Wilson Sonsini Goodrich & Ro Other $0 $0 $0 $0 xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi

UST Form 11-MOR (12/01/2021) 6

------

![LOGO](g847630dsp071.jpg)

lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii

UST Form 11-MOR (12/01/2021) 7

------

![LOGO](g847630dsp072.jpg)

xcix c c. All professional fees and expenses (debtor & committees) $1,921,489 $1,921,489 $1,921,489 $1,921,489 Part 6: Postpetition Taxes Current Month Cumulative a. Postpetition income taxes accrued (local, state, and federal) $0 $0 b. Postpetition income taxes paid (local, state, and federal) $0 $0 c. Postpetition employer payroll taxes accrued $47,289 $151,047 d. Postpetition employer payroll taxes paid $320,695 $761,457 e. Postpetition property taxes paid $3,036 $3,036 f. Postpetition other taxes accrued (local, state, and federal) $78,236 $132,884 g. Postpetition other taxes paid (local, state, and federal) $90,651 $95,921 Part 7: Questionnaire—During this reporting period: a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No b. Were any payments made outside the ordinary course of business Yes No without court approval? (if yes, see Instructions) c. Were any payments made to or on behalf of insiders? Yes No d. Are you current on postpetition tax return filings? Yes No e. Are you current on postpetition estimated tax payments? Yes No f. Were all trust fund taxes remitted on a current basis? Yes No g. Was there any postpetition borrowing, other than trade credit? Yes No (if yes, see Instructions) h. Were all payments made to or on behalf of professionals approved by Yes No N/A the court? i. Do you have: Worker's compensation insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) General liability insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) j. Has a plan of reorganization been filed with the court? Yes No k. Has a disclosure statement been filed with the court? Yes No l. Are you current with quarterly U.S. Trustee fees as Yes No set forth under 28 U.S.C. § 1930?

UST Form 11-MOR (12/01/2021) 8

------

![LOGO](g847630dsp073.jpg)

Part 8: Individual Chapter 11 Debtors (Only) a. Gross income (receipts) from salary and wages $0 b. Gross income (receipts) from self-employment $0 c. Gross income from all other sources $0 d. Total income in the reporting period (a+b+c) $0 e. Payroll deductions $0 f. Self-employment related expenses $0 g. Living expenses $0 h. All other expenses $0 i. Total expenses in the reporting period (e+f+g+h) $0 j. Difference between total income and total expenses (d-i) $0 k. List the total amount of all postpetition debts that are past due $0 l. Are you required to pay any Domestic Support Obligations as defined by 11 Yes No U.S.C § 101(14A)? m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A Privacy Act Statement 28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F). I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate. /s/ Joe Selsavage Joe Selsavage Signature of Responsible Party Printed Name of Responsible Party Interim Chief Executive Officer and Chief Financial and 06/30/2025 Title Date

UST Form 11-MOR (12/01/2021) 9

------

![LOGO](g847630dsp074.jpg)

UST Form 11-MOR (12/01/2021) 10

------

![LOGO](g847630dsp075.jpg)

UST Form 11-MOR (12/01/2021) 11

------

![LOGO](g847630dsp076.jpg)

UST Form 11-MOR (12/01/2021) 12

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 1** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 5/1/2025 - 5/31/2025 |
| **Cash Receipts and Disbursements** | **Cash Receipts and Disbursements** | **Cash Receipts and Disbursements** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **25-40977<br>23andMe,**<br> **Inc.** | **25-40976<br>23andMe<br>Holding**<br> **Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,**<br> **Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,**<br> **Inc** | **25-40980<br>Lemonaid<br>Health,**<br> **Inc.** | **25-40981<br>Lemonaid**<br> **Pharmacy<br>Holdings<br>Inc.** | **25-40982**<br> **LPharm**<br> **CS**<br> **LLC** | **25-40983<br>LPharm<br>INS<br>LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40975<br>LPRXOne<br>LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  Beginning bank cash balance | $45681 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total receipts | 16710 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total disbursements | (15614) |  |  |  |  |  |  |  |  |  |  |  |
|  **Ending bank cash balance** | $**46777** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

**Notes**: Cash Balance includes approximately $15.8M of Professional Fee Admin Reserves in the Carve Out Account.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 2** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 5/1/2025 - 5/31/2025 |
| **Balance Sheet** | **Balance Sheet** | **Balance Sheet** |

---

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Consolidated** | **25-40977<br>23andMe,<br>Inc.** | **25-40975<br>LPRXOne<br>LLC** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40976<br>23andMe<br>Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings<br>Inc.** | **25-40982**<br> **LPharm**<br> **CS**<br> **LLC** | **25-40983**<br> **LPharm**<br> **INS<br>LLC** | **25-40984**<br> **LPharm**<br> **RX LLC** | **25-40986**<br> **LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  **Assets** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **Current assets:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Cash and Cash Equivalents | $41054 | $41054 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Accounts receivable | 314 | 314 |  |  |  |  |  |  |  |  |  |  |  |
|  Prepaid Expenses | 17556 | 17509 |  | 47 |  |  |  |  |  |  |  |  |  |
|  Inventory | 14153 | 13968 | 185 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current assets** | **73078** | **72846** | **185** | **47** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Property and equipment, net | $1060 | $859 | $201 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Lease right-of-use assets, net | 479 | 381 | 98 |  |  |  |  |  |  |  |  |  |  |
|  Restricted cash | 5723 | 5723 |  |  |  |  |  |  |  |  |  |  |  |
|  Intangible assets, net | 42195 | 38450 |  | 3745 |  |  |  |  |  |  |  |  |  |
|  Other assets | 24879 | 24705 | 174 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total assets** | $**147414** | $**142963** | $**658** | $**3792** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |
|  **Liabilities** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **Current liabilities:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Accounts payable and accrued expenses | $42375 | $41640 | $259 | $475 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Deferred revenue | 42037 | 41155 | 494 | 388 |  |  |  |  |  |  |  |  |  |
|  Lease Liabilities | 2752 | 2752 |  |  |  |  |  |  |  |  |  |  |  |
|  Tax Payable | 249 | 249 |  |  |  |  |  |  |  |  |  |  |  |
|  Other Current Liabilities | 1361 | 1361 |  |  |  |  |  |  |  |  |  |  |  |
|  DIP Lending | 10000 | 10000 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current liabilities** | **98773** | **97157** | **753** | **863** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Other Liabilities | 224 | 224 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total liabilities not subject to compromise** | **98998** | **97382** | **753** | **863** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Liabilities subject to compromise:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Accounts payable and accrued payable | $11325 | $11196 | $62 | $67 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Lease liabilities | 21932 | 21838 | 94 |  |  |  |  |  |  |  |  |  |  |
|  Loss contingencies | 40620 | 40620 |  |  |  |  |  |  |  |  |  |  |  |
|  **Total liabilities** | **172875** | **171036** | **909** | **930** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Common Stock | $3 | $3 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Additional paid-in capital | 2427011 | 2427011 |  |  |  |  |  |  |  |  |  |  |  |
|  Accumulated Deficit - Retained Earnings | (67064) | (67064) |  |  |  |  |  |  |  |  |  |  |  |
|  Accumulated Deficit - Net Income | (2385411) | (2385411) |  |  |  |  |  |  |  |  |  |  |  |
|  **Total liabilities and equity** | $**147414** | $**145575** | $**909** | $**930** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

**Notes**: The Debtors maintain their books and records on a consolidated basis in the ordinary course of business, however, this MOR was prepared on an entity-by-entity basis. Accordingly, column "Consolidated" was included to provide a consolidated view of the Balance Sheet for reconciliation purposes only.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 3** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 5/1/2025 - 5/31/2025 |
| **Income Statement** | **Income Statement** | **Income Statement** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **25-40977<br>23andMe,<br>Inc.** | **25-40975<br>LPRXOne<br>LLC** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40976<br>23andMe<br>Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings<br>Inc.** | **25-40982<br>LPharm**<br> **CS**<br> **LLC** | **25-40983<br>LPharm**<br> **INS<br>LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985**<br> **LPRXThree<br>LLC** |
|  **Revenue:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Total consumer services revenue | $5921 | $— | $294 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total research services and other revenue | 182 |  |  |  |  |  |  |  |  |  |  |  |
|  Total product revenue |  | 1675 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total revenue** | **6103** | **1675** | **294** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Expenses:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Cost of revenue | $1824 | $936 | $822 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Sales and marketing | 1868 |  |  |  |  |  |  |  |  |  |  |  |
|  General and administrative | 7257 |  |  |  |  |  |  |  |  |  |  |  |
|  Research and development | 4613 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total expenses** | **15561** | **936** | **822** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Income (Loss) from operations | $(9459) | $739 | $(527) | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  **Interest and other (expense) income:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Total - Interest income | $28 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total - Other (expense) income | 4 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total interest and other (expense) income** | **32** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Reorganization items** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Professional fees | $(1159) | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Board fees | $(1394) |  |  |  |  |  |  |  |  |  |  |  |
|  Legal fees | $(10855) |  |  |  |  |  |  |  |  |  |  |  |
|  Public Relations | $(679) |  |  |  |  |  |  |  |  |  |  |  |
|  Gain/Loss on Sale of Subsidiary | $4316 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total Reorganization item gain (losses)** | **(9771)** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Net Loss | $(19197) | $739 | $(527) | $— | $— | $— | $— | $— | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Net income (loss)** | $**(19197)** | $**739** | $**(527)** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 4** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 5/1/2025 - 5/31/2025 |
| **Accounts Receivable Aging** | **Accounts Receivable Aging** | **Accounts Receivable Aging** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Current - 31** | **32 - 61** | **62 - 91** | **92+** | **Gross AR** | **Allowance for<br>Doubtful<br>Accounts** | **Net AR** |
| 25-40977 | 23andMe, Inc. | $230 | $– $| 84 | $500 | $814 | $500 | $314 |
| 25-40976 | 23andMe Holding Co. |  | – |  |  |  |  |  |
| 25-40978 | 23andMe Pharmacy Holdings, Inc. |  | – |  |  |  |  |  |
| 25-40979 | Lemonaid Community Pharmacy, Inc |  | – |  |  |  |  |  |
| 25-40980 | Lemonaid Health, Inc. |  | – |  |  |  |  |  |
| 25-40981 | Lemonaid Pharmacy Holdings Inc. |  | – |  |  |  |  |  |
| 25-40982 | LPharm CS LLC |  | – |  |  |  |  |  |
| 25-40983 | LPharm INS LLC |  | – |  |  |  |  |  |
| 25-40984 | LPharm RX LLC |  | – |  |  |  |  |  |
| 25-40975 | LPRXOne LLC |  | – |  |  |  |  |  |
| 25-40985 | LPRXThree LLC |  | – |  |  |  |  |  |
| 25-40986 | LPRXTwo LLC |  | – |  |  |  |  |  |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 5** |
| **In re: 23andMe Inc.** | Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 5/1/2025 - 5/31/2025 |
| **Postpetition Liabilities Aging** | **Postpetition Liabilities Aging** | **Postpetition Liabilities Aging** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **<u>Day Past Due</u>** | **<u>Day Past Due</u>** | **<u>Day Past Due</u>** | **<u>Day Past Due</u>** | **<u>Day Past Due</u>** | |
|  | **Current** | **1 - 30** | **31 - 60** | **61 - 90** | **91+** | **Total** |
|  Accounts payable and accrued expenses | 29624 | 462 | 18 | 569 | 25 | 30698 |
|  Deferred revenue |  |  |  |  |  |  |
|  Lease Liabilities |  |  |  |  |  |  |
|  Other Current Liabilities |  |  |  |  |  |  |
|  DIP Lending | 10000 |  |  |  |  | 10000 |
|  Other Liabilities |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total postpetition liabilities** | **39624** | **462** | **18** | **569** | **25** | **40698** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 6** |
| **In re: 23andMe Inc.** | Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 5/1/2025 - 5/31/2025 |
| **Payments to Insiders** | **Payments to Insiders** | **Payments to Insiders** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Case No.** | **Entity** | **Recipient** | **Total Payments** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25-40977 | 23andMe Inc. | Officer#1 | $57 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25-40977 | 23andMe Inc. | Officer#2 | $41 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25-40977 | 23andMe Inc. | Director#2 | $20 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25-40977 | 23andMe Inc. | Director#3 | $20 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25-40977 | 23andMe Inc. | Director#4 | $20 |
|  |  | **Total** | $**158** |

---

**Notes:**

With respect to insiders, all cash payments made were on account of ordinary course salaries and/or fees, benefits, authorized travel, and and expense reimbursements.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 7** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 5/1/2025 - 5/31/2025 |
| **Certification Regarding Postpetition Taxes** | **Certification Regarding Postpetition Taxes** | **Certification Regarding Postpetition Taxes** |

---

The Debtors hereby submit this attestation regarding postpetition tax payments during the period of May 1 through May 31, 2025.

The Debtors are authorized to pay Taxes and Fees that arise or accrue in the ordinary course of business on a postpetition basis consistent with prepetition practices. The Debtors believe that they are current with respect to any postpetition Taxes and Fees that have come due.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 6/30/2025 |
| Signature of Authorized Individual | Date |

---

<u>Joe Selsavage</u>   <u>6/30/2025</u> <br> Printed Name of Authorized Individual Date

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 8** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 5/1/2025 - 5/31/2025 |
|  **Schedule of Pre-Petition Payments** | **Schedule of Pre-Petition Payments** | **Schedule of Pre-Petition Payments** |

---

The Debtors hereby submit this attestation regarding prepetition payments during the period of May 1 through May 31, 2025

All payments made by the Debtors during the period of May 1 through May 31, 2025 (and included in the disbursements reported herein), were authorized under First Day Orders granted by the Court.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 6/30/2025 |
| Signature of Authorized Individual | Date |

---

<u>Joe Selsavage</u>   <u>6/30/2025</u> <br> Printed Name of Authorized Individual Date

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 9** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 5/1/2025 - 5/31/2025 |
| **Schedule of Payments to Insiders** | **Schedule of Payments to Insiders** | **Schedule of Payments to Insiders** |

---

The Debtors hereby submit this attestation regarding prepetition payments during the period of May 1 through May 31, 2025

With respect to insiders, all cash payments made were on account of ordinary course salaries and/or fees, benefits, authorized travel and expense reimbursements.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 6/30/2025 |
| Signature of Authorized Individual | Date |

---

<u>Joe Selsavage</u>   <u>6/30/2025</u> <br> Printed Name of Authorized Individual Date

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 10** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 5/1/2025 - 5/31/2025 |
|  **All Bank Statements and Bank Reconciliations for the Reporting Period** | **All Bank Statements and Bank Reconciliations for the Reporting Period** | **All Bank Statements and Bank Reconciliations for the Reporting Period** |

---

The Debtors hereby submit this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and journal entries.

The Debtors' standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting period. I attest that each of the Debtors' bank accounts has been reconciled in accordance with their standard practices.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 6/30/2025 |
| Signature of Authorized Individual | Date |

---

<u>Joe Selsavage</u>   <u>6/30/2025</u> <br> Printed Name of Authorized Individual Date

## Exhibit 99.4

**Exhibit 99.4** 

**UNITED STATES BANKRUPTCY COURT** 

**EASTERN DISTRICT OF MISSOURI** 

**EASTERN DIVISION** 

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;In re: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chapter 11 |
| &nbsp;&nbsp;&nbsp;23ANDME HOLDING CO., *et al.*,<sup>1</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Case No. 25-40976-357 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debtors. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Jointly Administered) |

---

**GLOBAL NOTES AND STATEMENTS OF LIMITATIONS, METHODOLOGY,** 

**AND DISCLAIMERS REGARDING THE DEBTORS' MONTHLY OPERATING REPORT** 

On March 23, 2025 (the "<u>Petition Date</u>"), the above-captioned debtors and debtors in possession (collectively, the "<u>Debtors</u>") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "<u>Bankruptcy Code</u>") in the United States Bankruptcy Court for the Eastern District of Missouri (the "<u>Court</u>"), thereby commencing these chapter 11 cases. The Debtors are operating their business and managing their property as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. On March 27, 2025, the Court entered an order authorizing the joint administration of these chapter 11 cases pursuant to rule 1015(b) of the Federal Rules of Bankruptcy Procedure [Docket No. 105]. On April 3, 2025, the United States Trustee for the Eastern District of Missouri (the "<u>U.S. Trustee</u>") appointed an official committee of unsecured creditors pursuant to section 1102(a)(1) of the Bankruptcy Code (the "<u>Creditors' Committee</u>") [Docket No. 159]. On July 15, 2025, the U.S. Trustee appointed an official committee of equity security holders (the "Official Equity Committee" and, together with the Creditors' Committee, the "<u>Committees</u>") [Docket No. 1008].

On July 14, 2025, the Debtors closed the sale of substantially all of their assets (the "<u>Sale</u>") to TTAM Research Institute (the "<u>Purchaser</u>") [Docket No. 994]<sup>2</sup>.

The following global notes and statements of limitations, methodology, and disclaimers should be referred to and referenced in connection with any review of this MOR (as defined below).

**1.** **General Methodology.** The Debtors are filing this consolidated monthly operating report
(" <u>MOR</u> ") for the period from June 1, 2025, through and including June 30, 2025 (the " <u>Reporting Period</u> "), solely for the purpose of complying with the monthly reporting requirements applicable in the
Debtors'

<sup>1</sup> The Debtors in each of these cases, along with the last four digits of each Debtor's federal tax identification number, are: 23andMe Holding Co. (0344), 23andMe, Inc. (7371), 23andMe Pharmacy Holdings, Inc. (4690), Lemonaid Community Pharmacy, Inc. (7330), Lemonaid Health, Inc. (6739), Lemonaid Pharmacy Holdings Inc. (6500), LPharm CS LLC (1125), LPharm INS LLC (9800), LPharm RX LLC (7746), LPRXOne LLC (3447), LPRXThree LLC (3852), and LPRXTwo LLC (1595). The Debtors' service address for purposes of these chapter 11 cases is: 870 Market Street, Room 415, San Francisco, CA 94102. 

<sup>2</sup> The Purchaser's asset purchase agreement provides that the Purchaser will acquire the Debtors' Lemonaid telehealth business pursuant to a chapter 11 plan to be proposed after the closing of the Sale, subject to higher or better offers.

------

chapter 11 cases. This MOR is (a) unaudited, has not been prepared in accordance with (i) Generally Accepted Accounting Principles in the United States ("U.S. GAAP") and does not include all of the information and footnotes required by U.S. GAAP, or (ii) federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any period reporting requirements thereunder and (b) remains subject to future adjustments. This MOR is not intended to reconcile any financial statements otherwise prepared or distributed by the Debtors. This MOR should not be relied upon by any person for information relating to the current or future financial condition of the Debtors or their affiliates, the occurrence or non-occurrence of any event, or the performance of any of the Debtors or their affiliates as the results of operations addressed herein are not necessarily indicative of results that may be expected from any other period or for the full year and may not reflect the combined results of the Debtors' operations, the Debtors' financial position, or the Debtors' schedule of receipts and disbursements in the future. The preparation of this MOR required the Debtors to make commercially reasonable estimates and assumptions with respect to the reported amounts of assets and liabilities at month end and the reported amounts of revenues and expenses during the applicable reporting periods. Actual results could differ materially from such estimates.

**2.** **Basis of Presentation.** In preparing this MOR, the Debtors relied on financial information from the books
and records available to them at the time of such preparation. The financial information contained herein is derived from the Debtors' books and records without, among other things, all adjustments or reclassifications that may be necessary or
typical for consolidated financial statements or to accord with U.S. GAAP. As a result, all information contained herein is subject to change, which could be material. Although the Debtors made commercially reasonable efforts to ensure the material
accuracy and completeness of this MOR and because the Debtors' accounting systems were developed to produce consolidated financial statements by business unit rather than financial statements by legal entity, it is possible that not all
assets, liabilities, income, or expenses have been attributed to the correct legal entity.

The information contained in this MOR has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtors believe that the financial information presented in this MOR could be subject to material change.

For the reasons discussed above, there can be no assurance that the financial information presented herein is complete, and readers are strongly cautioned not to place undue reliance on this MOR. Moreover, the results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the results of operations, financial position, and cash flows of the Debtors in the future.

**3.** **Reporting Period.** Unless otherwise noted herein, this MOR generally reflects the Debtors' books
and records for the applicable Reporting Period. Unless otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

**4.** **Consolidated Entity Accounts Payable and Disbursement Systems.** Receivables and payables among the
Debtors and their non-Debtor affiliates<sup>3</sup> are reported per the Debtors' unaudited books and records. As described more fully in the *Final Order (I) Authorizing (A) Continued Use of Cash Management System, (B) Maintenance of Bank Accounts and Business Forms, (C) Performance of Intercompany Transactions, And (D) Certain Prepetition Obligations to Be Honored; (II) Granting Administrative Expense Priority Status to Postpetition Intercompany Claims Against The Debtors; And (III) Granting Related Relief* [Docket No. 297], the Debtors utilize an integrated, centralized cash

<sup>3</sup> Non-Debtor affiliates exclude any controlling shareholder of 23andMe Holding Co.

------

management system in the ordinary course of business to collect, concentrate, and disburse funds generated from their operations. Cash is being received and disbursed by the Debtors during these chapter 11 cases in a manner consistent with the Debtors' historical cash management practices. 

&nbsp;&nbsp;&nbsp;&nbsp;**5.** **Accuracy.** The financial information disclosed herein was not prepared in accordance with federal or
state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling, or
transferring claims against or interests in the Debtors should evaluate this financial information in light of the purposes for which it was prepared. The Debtors and their advisors are not liable for and undertake no responsibility (i) to
indicate variations from state, federal, or other securities laws or (ii) for any evaluations of the Debtors, including of their financial condition, based on the information provided in this MOR or any other information.

**6.** **Debtor in Possession Financing.** On April 23, 2025, the Court entered the *Final Order (A) Authorizing the Debtors to Obtain Postpetition Financing, Grant Liens, Provide Superpriority Administrative Expense Claims and Use Cash Collateral, (B) Modifying the Automatic Stay, and (C) Granting Related Relief* [Docket
No. 313] (the " <u>DIP Order</u> "), authorizing the Debtors, jointly and severally, to obtain a non-amortizing, priming, super-priority senior secured postpetition credit facility (the
" <u>DIP Facility</u> ") in an aggregate principal amount of up to $35 million (the " <u>Facility Amount</u> "). Of the total Facility Amount, (a) $10 million became available following entry of the DIP Order, and (b)
the remaining $25 million became available on May 16, 2025, following the Debtors' announcement of an Acceptable Successful Bid (as defined in the DIP Credit Agreement (as defined below)), in each case, subject to the terms and
conditions set forth in DIP Order and that certain *Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement* by and among the
Debtors, as Borrowers, and JMB Capital Partners Lending, LLC (the " <u>DIP Lender</u> ") or its permitted designees or assignees, as Lender (as amended, modified, or supplemented from time to time, the " <u>DIP Credit Agreement</u> ").

On May 5, 2025, the Debtors made an initial draw of $10 million under the DIP Facility. On June 5, 2025, the Debtors and the DIP Lender entered into that certain *Second Amendment to Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement*, which, among other things, increased the Facility Amount by an additional $25 million [Docket No. 717]. On June 24, 2025, the Debtors made an additional draw of $15 million under the DIP Facility. On July 14, 2025, the Debtors paid the DIP Lender all outstanding amounts under the DIP Facility in connection with the Sale.

Please refer to the DIP Order for additional details.

**7.** **Payment of Prepetition Claims Pursuant to First Day Orders.** Following the Petition Date, the Court
entered various orders authorizing, but not directing, the Debtors to, among other things, pay certain prepetition: (a) charges assessed by the Debtors' banks; (b) insurance obligations; (c) employee wages, salaries, and related
items (including employee benefit programs); (d) taxes and assessments; (e) customer program obligations; and (f) critical vendor obligations (collectively, the " <u>First Day Orders</u> "). To the extent any payments were made during
the Reporting Period on account of prepetition claims pursuant to the authority granted to the Debtors by the Court under the First Day Orders, such payments have been included in this MOR (subject to the notes and statements and limitations
provided herein).

**8.** **Reservation of Rights.** The Debtors reserve all rights to amend or supplement this MOR in all respects,
as may be necessary or appropriate. Nothing contained in this MOR shall constitute a waiver of any of the Debtors' rights or an admission with respect to their chapter 11 cases.

------

**9.** **Insiders.** Information regarding the individuals listed as "insiders" in this MOR have been
included for informational purposes only. The Debtors do not take any position with respect to, and reserve all rights with respect to: (a) such person's influence over or control of the Debtors, (b) the management responsibilities
or functions of such individual, (c) the decision-making or corporate authority of such individual, and (d) whether such individual could successfully argue that he or she is not an "insider" under applicable law, including any
state, federal, or other securities law, or with respect to any theories of liability or for any other purpose.

**10.** **Currency.** All amounts shown in this MOR are in United States dollars unless otherwise stated.

**11.** **MOR Information Requests.** The Debtors and/or their advisors are managing an email address to which
parties may send requests for additional information from the Debtors regarding the information contained in this and all other MORs. For any such requests, please send an email to 23andMeInfo@ra.kroll.com.

**12.** **Specific MOR Disclosures.** 

**Notes to Part 1: Cash Receipts and Disbursements** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Figures include cash as reported in the Debtors' bank statements. Reconciliation differences will exist
between bank statement balances and balance sheet cash balances due to ordinary course timing differences between payment execution in the Debtors' financial system and disbursement of funds from Debtor bank accounts.

**Notes to Part 2: Asset and Liability Status** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• See "Basis of Presentation" notes above regarding certain adjustments or reclassifications applied at
a consolidated level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Because the Debtors' existing recording systems were not designed to distinguish between pre- and postpetition liabilities, the Debtors have commenced a process to distinguish between pre- and postpetition liabilities, the results of which are reflected in this
MOR. As the Debtors continue this process and additional information becomes available, the allocation of liabilities between prepetition and postpetition periods may change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Items (k–m)</u>: Prepetition liabilities (*i.e.*, items (k), (l), and (m)) reflect liabilities
included in "Liabilities subject to compromise" on the Debtors' balance sheet as well as other prepetition liabilities that may be uncompromised pursuant to the relief granted via the First Day Orders. The Debtors' inclusion
or exclusion of any amounts in the presentation of "liabilities subject to compromise" in the Balance Sheet is done solely to enable the Debtors to expeditiously prepare this MOR pursuant to the Debtors' reporting obligations and
does not indicate a view, of the Debtors or of any other person, as to whether and to what extent the respective liabilities may be impaired.

**Notes to Part 4: Income Statement** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• See "Basis of Presentation" notes above regarding certain adjustments or reclassifications applied at
a consolidated level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This MOR has not been subject to certain quarterly or annual adjustment procedures, including income tax
provision and impairment assessment procedures. The information presented herein may materially differ if such procedures were applied.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (b)</u>: "Cost of revenue" on the Debtors' balance sheet is classified as a cost of
goods sold (*i.e.*, item (b)). Cost of Revenue includes the day-to-day costs of operating the business like facility and equipment costs, and depreciation and
amortization.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Item (e): Depreciation and Amortization are netted with the totals for the Cost of Service, General and
Administrative and Other expenses and have not been broken out as a separate line item.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Item (f): Other expenses (*i.e.*, item (f)) include Research and Development expenses and other income.

**Notes to Part 5: Professional Fees and Expenses** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (c)</u>: Part 5(c) provides the total of professional fees and expenses paid presented in Part 5(a) and
Part 5(b), as well as professional fees and expenses paid for professionals employed by the Committees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors pay fees and expenses of Kroll Restructuring Administration LLC, as the Debtors' claims and
noticing agent, pursuant to the *Final Order Authorizing Appointment of Kroll Restructuring Administration LLC as Claims and Noticing Agent and Administrative Advisor Effective as of the Petition Date* [Docket No. 308].

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors pay fees and expenses of retained professionals in accordance with the Local Rules of Bankruptcy
Procedure for the Eastern District of Missouri.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors pay fees and expenses of ordinary course professionals in accordance with the *Order (I) Authorizing the Retention and Compensation of Certain Professionals Utilized in the Ordinary Course of Business and (II) Granting Related Relief* [Docket No. 354].

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors reimburse Alvarez & Marsal North America, LLC for its reasonable costs and expenses in
connection with the Debtors' Chief Restructuring Officer's appointment as the Foreign Representative in the Debtors' ancillary proceedings in the Supreme Court of British Columbia in Vancouver, British Columbia, pursuant to the
Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36 pursuant to the *Order (I) Authorizing Matthew Kvarda to Act as Foreign Representative; and (II) Granting Related Relief* [Docket No. 392].

**Notes to Part 6: Postpetition Taxes** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the ordinary course of business, the Debtors collect, withhold, and incur income taxes, franchise taxes, sales
and use taxes, personal property taxes, foreign taxes, and other governmental and regulatory and employee-related taxes, penalties, interests, assessments, and fees (collectively, the " <u>Taxes and Fees</u> "). On April 23, 2025, the
Court entered a final order [Docket No. 303] authorizing, but not directing, the Debtors to, among other things, pay Taxes and Fees that arise or accrue in the ordinary course of business on a postpetition basis consistent with prepetition
practices. The Debtors believe that they are current with respect to any postpetition Taxes and Fees that have come due.

**Notes to Part 7: Questionnaire** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (a)</u>: Pursuant to the relief granted in the Debtors' various First Day Orders, the Debtors have
made payments on account of prepetition debts as they come due in the ordinary course of business. Where applicable, details of these payments have been delivered to the required notice parties pursuant to the reporting requirements set forth in the
First Day Orders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (g)</u>: Please refer to the "Debtor in Possession Financing" notes above regarding approved
postpetition financing.

------

![LOGO](g847630dsp092.jpg)

UNITED STATES BANKRUPTCY COURT Eastern DISTRICT OF Missouri In Re. 23andMe, Inc. § Case No. 25-40977 § § Lead Case No. 25-40976 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 06/30/2025 Petition Date: 03/23/2025 Months Pending: 3 Industry Classification: 6 2 1 5 Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Employees (current): 227 Debtor's Full-Time Employees (as of date of order for relief): 262 Supporting Documentation (check all that are attached): (For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement) Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Thomas H. Riske Thomas H. Riske Signature of Responsible Party Printed Name of Responsible Party 07/31/2025 120 S. Central Avenue, Suite 1800, St. Louis, Missouri Date 63105 Address STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. §

UST Form 11-MOR (12/23/2022) 1

------

![LOGO](g847630dsp093.jpg)

Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $46,776,981 b. Total receipts (net of transfers between accounts) $20,441,175 $48,592,150 c. Total disbursements (net of transfers between accounts) $21,668,114 $55,092,081 d. Cash balance end of month (a+b-c) $45,550,041 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation (c+e) $21,668,114 $55,092,081 Part 2: Asset and Liability Status Current Month (Not generally applicable to Individual Debtors. See Instructions.) a. Accounts receivable (total net of allowance) $1,294,543 b. Accounts receivable over 90 days outstanding (net of allowance) $0 c. Inventory (Book Market Other (attach explanation)) $13,249,110 d Total current assets $63,963,176 e. Total assets $139,667,924 f. Postpetition payables (excluding taxes) $58,879,169 g. Postpetition payables past due (excluding taxes) $2,819,341 h. Postpetition taxes payable $50,976 i. Postpetition taxes past due $0 j. Total postpetition debt (f+h) $58,930,144 k. Prepetition secured debt $224,364 l. Prepetition priority debt $74,482 m. Prepetition unsecured debt $124,510,278 n. Total liabilities (debt) (j+k+l+m) $183,739,268 o. Ending equity/net worth (e-n) $-44,071,344 Part 3: Assets Sold or Transferred Current Month Cumulative a. Total cash sales price for assets sold/transferred outside the ordinary course of business $0 $0 b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business $0 $0 c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $0 $0 Part 4: Income Statement (Statement of Operations) Current Month Cumulative (Not generally applicable to Individual Debtors. See Instructions.) a. Gross income/sales (net of returns and allowances) $5,311,527 b. Cost of goods sold (inclusive of depreciation, if applicable) $1,766,537 c. Gross profit (a-b) $3,544,989 d. Selling expenses $2,333,784 e. General and administrative expenses $9,497,620 f. Other expenses $5,061,262 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $52,266 i. Taxes (local, state, and federal) $0 j. Reorganization items $10,418,632 k. Profit (loss) $-23,818,573 $-43,124,873

UST Form 11-MOR (12/23/2022) 2

------

![LOGO](g847630dsp094.jpg)

Part 5: Professional Fees and Expenses Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative a. Debtor's professional fees & expenses (bankruptcy) Aggregate Total $8,403,898 $9,218,068 $8,403,898 $9,218,068 Itemized Breakdown by Firm Firm Name Role i Alvarez & Marsal North AmericFinancial Professional $2,193,881 $2,443,881 $2,193,881 $2,443,881 ii Carmody MacDonald P.C. Local Counsel $207,714 $207,714 $207,714 $207,714 iii FTI Consulting, Inc. Other $0 $0 $0 $0 iv Goodwin Procter LLP Special Counsel $1,400,000 $1,400,000 $1,400,000 $1,400,000 v Kelley Drye & Warren LLP Other $0 $0 $0 $0 vi Kroll Restructuring Administra Other $650,000 $1,214,170 $650,000 $1,214,170 vii Lewis Rice LLC Special Counsel $0 $0 $0 $0 viii Moelis & Company, LLC Financial Professional $702,303 $702,303 $702,303 $702,303 ix Paul, Weiss, Rifkind, Wharton &Lead Counsel $3,250,000 $3,250,000 $3,250,000 $3,250,000 x Stinson LLP Other $0 $0 $0 $0 xi xii xiii xiv xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi

UST Form 11-MOR (12/23/2022) 3

------

![LOGO](g847630dsp095.jpg)

xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxviii

UST Form 11-MOR (12/23/2022) 4

------

![LOGO](g847630dsp096.jpg)

lxxix lxxx lxxxi lxxxii lxxxiii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative b. Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total $88,872 $1,196,192 $88,872 $1,196,192 Itemized Breakdown by Firm Firm Name Role i BDO Australia Other $0 $323 $0 $323 ii BDO USA LLP Other $0 $0 $0 $0 iii Captiva Advisory, Inc. Other $0 $2,951 $0 $2,951 iv Deloitte & Touche LLP Other $0 $0 $0 $0 v Duane Morris LLP Other $0 $4,881 $0 $4,881 vi FisherBroyles, LLP Other $0 $0 $0 $0 vii Foley & Lardner LLP Other $0 $0 $0 $0 viii Frank, Rimerman Co LLP Other $0 $0 $0 $0 ix Gibson, Dunn & Crutcher LLP Other $0 $0 $0 $0 x Greenberg Traurig LLP Other $0 $125,000 $0 $125,000 xi Hintze Law PLLC Other $0 $0 $0 $0 xii KPMG LLP Other $0 $0 $0 $0 xiii McCarthy Tétrault LLP Other $88,872 $138,872 $88,872 $138,872 xiv McDonnell Boehnen Hulbert & Other $0 $0 $0 $0

UST Form 11-MOR (12/23/2022) 5

------

![LOGO](g847630dsp097.jpg)

xv Morgan, Lewis & Bockius LLP Other $0 $530,503 $0 $530,503 xvi Osler Hoskin & Harcourt LLP Other $0 $4,075 $0 $4,075 xvii Quarles & Brady LLP Other $0 $0 $0 $0 xviii Reevemark, LLC Other $0 $388,900 $0 $388,900 xix Ryan, LLC Other $0 $0 $0 $0 xx Scale Strategy Operations LLC Other $0 $0 $0 $0 xxi Sheppard Mullin Other $0 $686 $0 $686 xxii Wilson Sonsini Goodrich & RosOther $0 $0 $0 $0 xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi

UST Form 11-MOR (12/23/2022) 6

------

![LOGO](g847630dsp098.jpg)

lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxviii lxxix lxxx lxxxi lxxxii lxxxiii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii

UST Form 11-MOR (12/23/2022) 7

------

![LOGO](g847630dsp099.jpg)

xcix c c. All professional fees and expenses (debtor & committees) $8,492,771 $10,414,260 $8,492,771 $10,414,260 Part 6: Postpetition Taxes Current Month Cumulative a. Postpetition income taxes accrued (local, state, and federal) $0 $0 b. Postpetition income taxes paid (local, state, and federal) $0 $0 c. Postpetition employer payroll taxes accrued $13,974 $165,021 d. Postpetition employer payroll taxes paid $259,480 $1,020,937 e. Postpetition property taxes paid $0 $3,036 f. Postpetition other taxes accrued (local, state, and federal) $37,002 $169,886 g. Postpetition other taxes paid (local, state, and federal) $9,546 $105,467 Part 7: Questionnaire—During this reporting period: a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No b. Were any payments made outside the ordinary course of business Yes No without court approval? (if yes, see Instructions) c. Were any payments made to or on behalf of insiders? Yes No d. Are you current on postpetition tax return filings? Yes No e. Are you current on postpetition estimated tax payments? Yes No f. Were all trust fund taxes remitted on a current basis? Yes No g. Was there any postpetition borrowing, other than trade credit? Yes No (if yes, see Instructions) h. Were all payments made to or on behalf of professionals approved by Yes No N/A the court? i. Do you have: Worker's compensation insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) General liability insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) j. Has a plan of reorganization been filed with the court? Yes No k. Has a disclosure statement been filed with the court? Yes No l. Are you current with quarterly U.S. Trustee fees as Yes No set forth under 28 U.S.C. § 1930?

UST Form 11-MOR (12/23/2022) 8

------

![LOGO](g847630dsp100.jpg)

Part 8: Individual Chapter 11 Debtors (Only) a. Gross income (receipts) from salary and wages $0 b. Gross income (receipts) from self-employment $0 c. Gross income from all other sources $0 d. Total income in the reporting period (a+b+c) $0 e. Payroll deductions $0 f. Self-employment related expenses $0 g. Living expenses $0 h. All other expenses $0 i. Total expenses in the reporting period (e+f+g+h) $0 j. Difference between total income and total expenses (d-i) $0 k. List the total amount of all postpetition debts that are past due $0 l. Are you required to pay any Domestic Support Obligations as defined by 11 Yes No U.S.C § 101(14A)? m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A Privacy Act Statement 28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/ eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F). I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate. /s/ Joe Selsavage Joe Selsavage Signature of Responsible Party Printed Name of Responsible Party Interim Chief Executive Officer and Chief Financial and 07/31/2025 Title Date

UST Form 11-MOR (12/23/2022) 9

------

![LOGO](g847630dsp101.jpg)

UST Form 11-MOR (12/23/2022) 10

------

![LOGO](g847630dsp102.jpg)

UST Form 11-MOR (12/23/2022) 11

------

![LOGO](g847630dsp103.jpg)

UST Form 11-MOR (12/23/2022) 12

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 1** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 6/1/2025 -6/30/2025 |
| **Cash Receipts and Disbursements** | **Cash Receipts and Disbursements** | **Cash Receipts and Disbursements** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **25-40977<br>23andMe,**<br> **Inc.** | **25-40976<br>23andMe**<br> **Holding<br>Co.** | **25-40978<br>23andMe**<br> **Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid**<br> **Community<br>Pharmacy,<br>Inc** | **25-40980<br>Lemonaid**<br> **Health,**<br> **Inc.** | **25-40981<br>Lemonaid**<br> **Pharmacy<br>Holdings<br>Inc.** | **25-40982<br>LPharm**<br> **CS**<br> **LLC** | **25-40983<br>LPharm**<br> **INS**<br> **LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40975<br>LPRXOne<br>LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  Beginning bank cash balance | $46777 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total receipts | 20441 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total disbursements | (21668) |  |  |  |  |  |  |  |  |  |  |  |
|  **Ending bank cash balance** | $**45550** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

**Notes**: Cash Balance includes approximately $21.5M of Professional Fee Admin Reserves in the Carve Out Account.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 2** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 6/1/2025 - 6/30/2025 |
| **Balance Sheet** | **Balance Sheet** | **Balance Sheet** |

---

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Consolidated** | **25-40977<br>23andMe,<br>Inc.** | **25-40975<br>LPRXOne<br>LLC** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40976<br>23andMe<br>Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings<br>Inc.** | **25-40982<br>LPharm<br>CS LLC** | **25-40983<br>LPharm<br>INS<br>LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  **Assets** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **Current assets:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Cash and Cash Equivalents | $39828 | $39828 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Accounts receivable | 1295 | 1295 |  |  |  |  |  |  |  |  |  |  |  |
|  Prepaid Expenses | 9628 | 9592 |  | 36 |  |  |  |  |  |  |  |  |  |
|  Inventory | 13439 | 13249 | 190 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current assets** | **64189** | **63963** | **190** | **36** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Property and equipment, net | $982 | $720 | $262 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Lease right-of-use assets, net | 452 | 436 | 16 |  |  |  |  |  |  |  |  |  |  |
|  Restricted cash | 5723 | 5723 |  |  |  |  |  |  |  |  |  |  |  |
|  Intangible assets, net | 42421 | 38494 |  | 3928 |  |  |  |  |  |  |  |  |  |
|  Other assets | 30562 | 30332 | 230 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total assets** | $**144328** | $**139668** | $**696** | $**3963** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Liabilities** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Current liabilities:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Accounts payable and accrued expenses | $41868 | $41074 | $318 | $475 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Deferred revenue | 41057 | 40266 | 443 | 348 |  |  |  |  |  |  |  |  |  |
|  Lease Liabilities | 2101 | 2014 | 87 |  |  |  |  |  |  |  |  |  |  |
|  Tax Payable | 74 | 74 |  |  |  |  |  |  |  |  |  |  |  |
|  Other Current Liabilities | 1401 | 1401 |  |  |  |  |  |  |  |  |  |  |  |
|  DIP Lending | 25000 | 25000 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current liabilities** | **111501** | **109830** | **848** | **823** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Other Liabilities | 224 | 224 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total liabilities not subject to compromise** | **111725** | **110054** | **848** | **823** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Liabilities subject to compromise:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Accounts payable and accrued payable | $11049 | $10920 | $62 | $67 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Lease liabilities | 18104 | 18104 |  |  |  |  |  |  |  |  |  |  |  |
|  Loss contingencies | 44610 | 44610 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total liabilities** | **185489** | **183688** | **910** | **890** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Common Stock | $3 | $3 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Additional paid-in capital | 2434938 | 2434938 |  |  |  |  |  |  |  |  |  |  |  |
|  Accumulated Deficit - Retained Earnings | (67064) | (67064) |  |  |  |  |  |  |  |  |  |  |  |
|  Accumulated Deficit - Net Income | (2409037) | (2409037) |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total liabilities and equity** | $**144328** | $**142528** | $**910** | $**890** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

**Notes**: The Debtors maintain their books and records on a consolidated basis in the ordinary course of business, however, this MOR was prepared on an entity-by-entity basis. Accordingly, column "Consolidated" was included to provide a consolidated view of the Balance Sheet for reconciliation purposes only.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 3** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 6/1/2025 - 6/30/2025 |
| **Income Statement** | **Income Statement** | **Income Statement** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **25-40977<br>23andMe,<br>Inc.** | **25-40975<br>LPRXOne<br>LLC** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40976<br>23andMe<br>Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings<br>Inc.** | **25-40982<br>LPharm<br>CS LLC** | **25-40983<br>LPharm<br>INS<br>LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985**<br> **LPRXThree<br>LLC** |
|  **Revenue:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Total consumer services revenue | $5020 | $— | $268 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total research services and other revenue | 292 |  |  |  |  |  |  |  |  |  |  |  |
|  Total product revenue |  | 1521 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total revenue** | **5312** | **1521** | **268** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Expenses:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Cost of revenue | $1767 | $813 | $784 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Sales and marketing | 2334 |  |  |  |  |  |  |  |  |  |  |  |
|  General and administrative | 9498 |  |  |  |  |  |  |  |  |  |  |  |
|  Research and development | 5054 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total expenses** | **18652** | **813** | **784** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Income (Loss) from operations | $(13341) | $708 | $(516) | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  **Interest and other (expense) income:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Total - Interest income | $(52) | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total - Other (expense) income | (7) |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total interest and other (expense) income** | **(59)** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Reorganization items** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Professional fees | $(1442) | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Board fees | $(117) |  |  |  |  |  |  |  |  |  |  |  |
|  Legal fees | $(12309) |  |  |  |  |  |  |  |  |  |  |  |
|  Public Relations | $(40) |  |  |  |  |  |  |  |  |  |  |  |
|  Gain/Loss on Sale of Subsidiary | $3489 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total Reorganization item gain (losses)** | **(10419)** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Net Loss | $(23819) | $708 | $(516) | $— | $— | $— | $— | $— | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Net income (loss)** | $**(23819)** | $**708** | $**(516)** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 4** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 6/1/2025 -6/30/2025 |
| **Accounts Receivable Aging** | **Accounts Receivable Aging** | **Accounts Receivable Aging** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Current -31** | **32 -61** | **62 -91** | **92+** | **Gross AR** | **Allowance for<br>Doubtful<br>Accounts** | **Net AR** |
| 25-40977 | 23andMe, Inc. | $1295 | $– $|  | $500 | $1795 | $500 | $1295 |
| 25-40976 | 23andMe Holding Co. |  | – |  |  |  |  |  |
| 25-40978 | 23andMe Pharmacy Holdings, Inc. |  | – |  |  |  |  |  |
| 25-40979 | Lemonaid Community Pharmacy, Inc |  | – |  |  |  |  |  |
| 25-40980 | Lemonaid Health, Inc. |  | – |  |  |  |  |  |
| 25-40981 | Lemonaid Pharmacy Holdings Inc. |  | – |  |  |  |  |  |
| 25-40982 | LPharm CS LLC |  | – |  |  |  |  |  |
| 25-40983 | LPharm INS LLC |  | – |  |  |  |  |  |
| 25-40984 | LPharm RX LLC |  | – |  |  |  |  |  |
| 25-40975 | LPRXOne LLC |  | – |  |  |  |  |  |
| 25-40985 | LPRXThree LLC |  | – |  |  |  |  |  |
| 25-40986 | LPRXTwo LLC |  | – |  |  |  |  |  |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 5** |
| **In re: 23andMe Inc.** | Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 6/1/2025 -6/30/2025 |
| **Postpetition Liabilities Aging** | **Postpetition Liabilities Aging** | **Postpetition Liabilities Aging** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Day Past Due** | **Day Past Due** | **Day Past Due** | **Day Past Due** | **Day Past Due** | **Day Past Due** |
|  | **Current** | **1 - 30** | **31 - 60** | **61 - 90** | **91+** | **Total** |
|  Accounts payable and accrued expenses | 31106 | 2551 | 69 | 93 | 60 | **33879** |
|  Deferred revenue |  |  |  |  |  |  |
|  Lease Liabilities |  |  |  |  |  |  |
|  Other Current Liabilities |  |  |  |  |  |  |
|  DIP Lending | 25000 |  |  |  |  | 25000 |
|  Other Liabilities |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total postpetition liabilities** | **56106** | **2551** | **69** | **93** | **60** | **58879** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 6** |
| **In re: 23andMe Inc.** | Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 6/1/2025 - 6/30/2025 |
| **Payments to Insiders** | **Payments to Insiders** | **Payments to Insiders** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Case No.** | **Entity** | **Recipient** | **Total Payments** |
| 25-40977 | 23andMe Inc. | Officer#1 | $61 |
| 25-40977 | 23andMe Inc. | Officer#2 | $44 |
| 25-40977 | 23andMe Inc. | Director#2 | $20 |
| 25-40977 | 23andMe Inc. | Director#3 | $20 |
| 25-40977 | 23andMe Inc. | Director#4 | $20 |
|  |  | **Total** | **$165** |

---

**<u>Notes:</u>** 

With respect to insiders, all cash payments made were on account of ordinary course salaries and/or fees, benefits, authorized travel,and and expense reimbursements.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 7** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 6/1/2025 - 6/30/2025 |
| **Certification Regarding Postpetition Taxes** | **Certification Regarding Postpetition Taxes** | **Certification Regarding Postpetition Taxes** |

---

The Debtors hereby submit this attestation regarding postpetition tax payments during the period of June 1 through June 30, 2025.

The Debtors are authorized to pay Taxes and Fees that arise or accrue in the ordinary course of business on a postpetition basis consistent with prepetition practices. The Debtors believe that they are current with respect to any postpetition Taxes and Fees that have come due.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 7/31/2025 |
| Signature of Authorized Individual | Date |

---

<u>Joe Selsavage</u>   <u>7/31/2025</u> <br> Printed Name of Authorized Individual Date

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 8** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 6/1/2025 - 6/30/2025 |
| **Schedule of Pre-Petition Payments** | **Schedule of Pre-Petition Payments** | **Schedule of Pre-Petition Payments** |

---

---

| |
|:---|
| The Debtors hereby submit this attestation regarding prepetition payments during the period of June 1 through |
| June 30, 2025<br>All payments made by the Debtors during the period of June 1 through June 30, 2025 (and included in the disbursements reported herein), were authorized under First Day Orders granted by the Court.<br>|

---

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 7/31/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 7/31/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit -9** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 6/1/2025 - 6/30/2025 |
| **Schedule of Payments to Insiders** | **Schedule of Payments to Insiders** | **Schedule of Payments to Insiders** |

---

The Debtors hereby submit this attestation regarding prepetition payments during the period of June 1 through June 30, 2025

With respect to insiders, all cash payments made were on account of ordinary course salaries and/or fees, benefits, authorized travel and expense reimbursements.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 7/31/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 7/31/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit -10** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
|  | Reporting Period: | 6/1/2025 - 6/30/2025 |
| **All Bank Statements and Bank Reconciliations for the Reporting Period** | **All Bank Statements and Bank Reconciliations for the Reporting Period** | **All Bank Statements and Bank Reconciliations for the Reporting Period** |

---

The Debtors hereby submit this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and journal entries.

The Debtors' standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting period. I attest that each of the Debtors' bank accounts has been reconciled in accordance with their standard practices.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 7/31/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 7/31/2025 |
| Printed Name of Authorized Individual | Date |

---

## Exhibit 99.5

**Exhibit 99.5** 

**UNITED STATES BANKRUPTCY COURT** 

**EASTERN DISTRICT OF MISSOURI** 

**EASTERN DIVISION** 

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;In re: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chapter 11 |
| &nbsp;&nbsp;&nbsp;23ANDME HOLDING CO., *et al.*,<sup>1</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Case No. 25-40976-357 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debtors. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Jointly Administered) |

---

**GLOBAL NOTES AND STATEMENTS OF LIMITATIONS, METHODOLOGY,** 

**AND DISCLAIMERS REGARDING THE DEBTORS' MONTHLY OPERATING REPORT** 

On March 23, 2025 (the "<u>Petition Date</u>"), the above-captioned debtors and debtors in possession (collectively, the "<u>Debtors</u>") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "<u>Bankruptcy Code</u>") in the United States Bankruptcy Court for the Eastern District of Missouri (the "<u>Court</u>"), thereby commencing these chapter 11 cases. The Debtors are operating their business and managing their property as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. On March 27, 2025, the Court entered an order authorizing the joint administration of these chapter 11 cases pursuant to rule 1015(b) of the Federal Rules of Bankruptcy Procedure [Docket No. 105]. On April 3, 2025, the United States Trustee for the Eastern District of Missouri (the "<u>U.S. Trustee</u>") appointed an official committee of unsecured creditors pursuant to section 1102(a)(1) of the Bankruptcy Code (the "<u>Creditors' Committee</u>") [Docket No. 159]. On July 15, 2025, the U.S. Trustee appointed an official committee of equity security holders (the "<u>Official Equity Committee</u>" and, together with the Creditors' Committee, the "<u>Committees</u>") [Docket No. 1008].

On August 15, 2025, the Debtors filed the (a) *Joint Chapter 11 Plan of Chrome Holding Co. and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code* [Docket No. 1113] (as modified, amended, or supplemented from time to time, the "<u>Plan</u>") and (b) *Disclosure Statement for the Joint Chapter 11 Plan of Chrome Holding Co. and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code* [Docket No. 1114] (as modified, amended, or supplemented from time to time, the "<u>Disclosure Statement</u>").

The following global notes and statements of limitations, methodology, and disclaimers should be referred to and referenced in connection with any review of this MOR (as defined below).

<sup>1</sup> The Debtors in each of these cases, along with the last four digits of each Debtor's federal tax identification number, are: 23andMe Holding Co. (0344), 23andMe, Inc. (7371), 23andMe Pharmacy Holdings, Inc. (4690), Lemonaid Community Pharmacy, Inc. (7330), Lemonaid Health, Inc. (6739), Lemonaid Pharmacy Holdings Inc. (6500), LPharm CS LLC (1125), LPharm INS LLC (9800), LPharm RX LLC (7746), LPRXOne LLC (3447), LPRXThree LLC (3852), and LPRXTwo LLC (1595). The Debtors' service address for purposes of these chapter 11 cases is: 870 Market Street, Room 415, San Francisco, CA 94102. 

------

**1.** **General Methodology.** The Debtors are filing this consolidated monthly operating report
("MOR") for the period from July 1, 2025, through and including July 31, 2025 (the "Reporting Period"), solely for the purpose of complying with the monthly reporting requirements applicable in the Debtors'
chapter 11 cases. This MOR is (a) unaudited, has not been prepared in accordance with (i) Generally Accepted Accounting Principles in the United States (" <u>U.S. GAAP</u> ") and does not include all of the information and
footnotes required by U.S. GAAP, or (ii) federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any period reporting requirements thereunder and
(b) remains subject to future adjustments. This MOR is not intended to reconcile any financial statements otherwise prepared or distributed by the Debtors. This MOR should not be relied upon by any person for information relating to the current
or future financial condition of the Debtors or their affiliates, the occurrence or non-occurrence of any event, or the performance of any of the Debtors or their affiliates as the results of operations
addressed herein are not necessarily indicative of results that may be expected from any other period or for the full year and may not reflect the combined results of the Debtors' operations, the Debtors' financial position, or the
Debtors' schedule of receipts and disbursements in the future. The preparation of this MOR required the Debtors to make commercially reasonable estimates and assumptions with respect to the reported amounts of assets and liabilities at month
end and the reported amounts of revenues and expenses during the applicable reporting periods. Actual results could differ materially from such estimates.

**2.** **Basis of Presentation.** In preparing this MOR, the Debtors relied on financial information from the books
and records available to them at the time of such preparation. The financial information contained herein is derived from the Debtors' books and records without, among other things, all adjustments or reclassifications that may be necessary or
typical for consolidated financial statements or to accord with U.S. GAAP. As a result, all information contained herein is subject to change, which could be material. Although the Debtors made commercially reasonable efforts to ensure the material
accuracy and completeness of this MOR and because the Debtors' accounting systems were developed to produce consolidated financial statements by business unit rather than financial statements by legal entity, it is possible that not all
assets, liabilities, income, or expenses have been attributed to the correct legal entity.

The information contained in this MOR has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtors believe that the financial information presented in this MOR could be subject to material change.

For the reasons discussed above, there can be no assurance that the financial information presented herein is complete, and readers are strongly cautioned not to place undue reliance on this MOR. Moreover, the results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the results of operations, financial position, and cash flows of the Debtors in the future.

**3.** **Reporting Period.** Unless otherwise noted herein, this MOR generally reflects the Debtors' books
and records for the applicable Reporting Period. Unless otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

**4.** **Consolidated Entity Accounts Payable and Disbursement Systems.** Receivables and payables among the
Debtors and their non-Debtor affiliates<sup>2</sup> are reported per the Debtors' unaudited books and records. As described more fully in the *Final Order (I) Authorizing (A) Continued Use of Cash Management System, (B) Maintenance of Bank Accounts and Business Forms, (C) Performance of Intercompany Transactions, And (D) Certain Prepetition Obligations to Be Honored; (II) Granting Administrative Expense Priority Status to Postpetition Intercompany Claims Against The Debtors; And* 

<sup>2</sup> Non-Debtor affiliates exclude any controlling shareholder of Chrome Holding Co. f/ka/ 23andMe Holding Co.

------

*(III) Granting Related Relief* [Docket No. 297], the Debtors utilize an integrated, centralized cash management system in the ordinary course of business to collect, concentrate, and disburse funds generated from their operations. Cash is being received and disbursed by the Debtors during these chapter 11 cases in a manner consistent with the Debtors' historical cash management practices. <br>

**5.** **Accuracy.** The financial information disclosed herein was not prepared in accordance with federal or
state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling, or
transferring claims against or interests in the Debtors should evaluate this financial information in light of the purposes for which it was prepared. The Debtors and their advisors are not liable for and undertake no responsibility (a) to
indicate variations from state, federal, or other securities laws or (b) for any evaluations of the Debtors, including of their financial condition, based on the information provided in this MOR or any other information.

**6.** **Debtor in Possession Financing.** On April 23, 2025, the Court entered the *Final Order (A) Authorizing the Debtors to Obtain Postpetition Financing, Grant Liens, Provide Superpriority Administrative Expense Claims and Use Cash Collateral, (B) Modifying the Automatic Stay, and (C) Granting Related Relief* [Docket No. 313] (the " <u>DIP Order</u> "), authorizing the Debtors, jointly and severally, to obtain a non-amortizing, priming,
super-priority senior secured postpetition credit facility (the " <u>DIP Facility</u> ") in an aggregate principal amount of up to $35 million (the " <u>Facility Amount</u> "). Of the total Facility Amount, (a)
$10 million became available following entry of the DIP Order, and (b) the remaining $25 million became available on May 16, 2025, following the Debtors' announcement of an Acceptable Successful Bid (as defined in the DIP
Credit Agreement (as defined below)), in each case, subject to the terms and conditions set forth in DIP Order and that certain *Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement* by and among the Debtors, as Borrowers, and JMB Capital Partners Lending, LLC (the " <u>DIP Lender</u> ")
or its permitted designees or assignees, as Lender (as amended, modified, or supplemented from time to time, the " <u>DIP Credit Agreement</u> ").

On May 5, 2025, the Debtors made an initial draw of $10 million under the DIP Facility. On June 5, 2025, the Debtors and the DIP Lender entered into that certain *Second Amendment to Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement*, which, among other things, increased the Facility Amount by an additional $25 million [Docket No. 717]. On June 24, 2025, the Debtors made an additional draw of $15 million under the DIP Facility. On July 14, 2025, the Debtors paid the DIP Lender all outstanding amounts under the DIP Facility in connection with the Sale (as defined below) (the "<u>DIP Repayment</u>").

Please refer to the DIP Order for additional details.

**7.** **Asset Purchase**. On June 27, 2025, the Court entered an order authorizing the sale (the
" <u>Sale</u> ") of substantially all of the Debtors' assets to 23andMe Research Institute f/k/a TTAM Research Institute (the " <u>Purchaser</u> "). On July 14, 2025, the Debtors and the Purchaser closed the Sale.<sup>3</sup> As a result of the Sale, the Debtors have made certain adjustments to their reporting methodology as disclosed herein or in this MOR.

<sup>3</sup> The Purchaser's asset purchase agreement provides that the Purchaser will acquire the Debtors' Lemonaid telehealth business pursuant to a chapter 11 plan to be proposed after the closing of the Sale, subject to higher or better offers.

------

**8.** **Payment of Prepetition Claims Pursuant to First Day Orders.** Following the Petition Date, the Court
entered various orders authorizing, but not directing, the Debtors to, among other things, pay certain prepetition: (a) charges assessed by the Debtors' banks; (b) insurance obligations; (c) employee wages, salaries, and related
items (including employee benefit programs); (d) taxes and assessments; (e) customer program obligations; and (f) critical vendor obligations (collectively, the " <u>First Day Orders</u> "). To the extent any payments were made
during the Reporting Period on account of prepetition claims pursuant to the authority granted to the Debtors by the Court under the First Day Orders, such payments have been included in this MOR (subject to the notes and statements and limitations
provided herein).

**9.** **Reservation of Rights.** The Debtors reserve all rights to amend or supplement this MOR in all respects,
as may be necessary or appropriate. Nothing contained in this MOR shall constitute a waiver of any of the Debtors' rights or an admission with respect to their chapter 11 cases.

**10.** **Insiders.** Information regarding the individuals listed as "insiders" in this MOR have been
included for informational purposes only. The Debtors do not take any position with respect to, and reserve all rights with respect to: (a) such person's influence over or control of the Debtors, (b) the management responsibilities
or functions of such individual, (c) the decision-making or corporate authority of such individual, and (d) whether such individual could successfully argue that he or she is not an "insider" under applicable law, including any
state, federal, or other securities law, or with respect to any theories of liability or for any other purpose.

**11.** **Currency.** All amounts shown in this MOR are in United States dollars unless otherwise stated.

**12.** **MOR Information Requests.** The Debtors and/or their advisors are managing an email address to which
parties may send requests for additional information from the Debtors regarding the information contained in this and all other MORs. For any such requests, please send an email to 23andMeInfo@ra.kroll.com.

**13.** **Specific MOR Disclosures.** 

**Notes to Part 1: Cash Receipts and Disbursements** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Figures include cash as reported in the Debtors' bank statements. Reconciliation differences will exist
between bank statement balances and balance sheet cash balances due to ordinary course timing differences between payment execution in the Debtors' financial system and disbursement of funds from the Debtors' bank accounts. In addition,
certain reconciliation differences will exist as a result of the Sale and certain payment and reimbursement mechanics (the " <u>Payment Mechanics</u> ") between the Debtors and the Purchaser outlined in that certain (a) Asset Purchase
Agreement, dated as of June 13, 2025, by and among Chrome Holding Co. f/k/a 23andMe Holding Co. (" <u>HoldCo</u> "), the Additional Sellers (as defined therein), and the Purchaser and (b) Transition Services Agreement dated as of
July 14, 2025 by and among HoldCo, the Additional Sellers, and the Purchaser Parties (as defined therein) (collectively, the " <u>Sale Agreements</u> ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (a)-(d)</u>: figures exclude certain disbursements made by the Debtors for the benefit of the Purchaser
during the Reporting Period, which were reimbursed by the Purchaser in connection with the Payment Mechanics.

------

**Notes to Part 2: Asset and Liability Status** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• See "Basis of Presentation" notes above regarding certain adjustments or reclassifications applied at
a consolidated level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Because the Debtors' existing recording systems were not designed to distinguish between pre- and postpetition liabilities, the Debtors have commenced a process to distinguish between pre- and postpetition liabilities, the results of which are reflected in this
MOR. As the Debtors continue this process and additional information becomes available, the allocation of liabilities between prepetition and postpetition periods may change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Items (k–m)</u>: Prepetition liabilities (i. *e.*, items (k), (l), and (m)) reflect liabilities
included in "Liabilities subject to compromise" on the Debtors' balance sheet as well as other prepetition liabilities that may be uncompromised pursuant to the relief granted via the First Day Orders. The Debtors' inclusion
or exclusion of any amounts in the presentation of "liabilities subject to compromise" in the Balance Sheet is done solely to enable the Debtors to expeditiously prepare this MOR pursuant to the Debtors' reporting obligations and
does not indicate a view, of the Debtors or of any other person, as to whether and to what extent the respective liabilities may be impaired.

**Note to Part 3: Assets Sold or Transferred** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (b)</u>: Pursuant to the Sale Agreements, the Debtors, or the Purchaser on behalf of the Debtors, made
certain payments to third parties in connection with the Sale. Such payments include cure amounts associated with contracts the Debtors assumed and assigned to the Purchaser, the DIP Repayment, and certain escrow fees.

**Notes to Part 4: Income Statement** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• See "Basis of Presentation" notes above regarding certain adjustments or reclassifications applied at
a consolidated level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This MOR has not been subject to certain quarterly or annual adjustment procedures, including income tax
provision and impairment assessment procedures. The information presented herein may materially differ if such procedures were applied.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (b)</u>: "Cost of revenue" on the Debtors' balance sheet is classified as a cost of
goods sold (i. *e.*, item (b)). Cost of Revenue includes the day-to-day costs of operating the business like facility and equipment costs, and depreciation and
amortization.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (e)</u>: Depreciation and Amortization are netted with the totals for the Cost of Service, General and
Administrative and Other expenses and have not been broken out as a separate line item.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (f)</u>: Other expenses (i. *e.*, item (f)) include Research and Development expenses and other
income.

**Notes to Part 5: Professional Fees and Expenses** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (c)</u>: Part 5(c) provides the total of professional fees and expenses paid presented in Part 5(a) and
Part 5(b), as well as professional fees and expenses paid for professionals employed by the Committees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors pay fees and expenses of Kroll Restructuring Administration LLC, as the Debtors' claims and
noticing agent, pursuant to the *Final Order Authorizing Appointment of Kroll Restructuring Administration LLC as Claims and Noticing Agent and Administrative Advisor Effective as of the Petition Date* [Docket No. 308].

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors pay fees and expenses of retained professionals in accordance with the Local Rules of Bankruptcy
Procedure for the Eastern District of Missouri.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors pay fees and expenses of ordinary course professionals in accordance with the *Order (I) Authorizing the Retention and Compensation of Certain Professionals Utilized in the Ordinary Course of Business and (II) Granting Related Relief* [Docket No. 354].

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Debtors reimburse Alvarez & Marsal North America, LLC for its reasonable costs and expenses in
connection with the Debtors' Chief Restructuring Officer's appointment as the Foreign Representative in the Debtors' ancillary proceedings in the Supreme Court of British Columbia in Vancouver, British Columbia, pursuant to the
Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36 pursuant to the *Order (I) Authorizing Matthew Kvarda to Act as Foreign Representative; and (II) Granting Related Relief* [Docket No. 392].

**Notes to Part 6: Postpetition Taxes** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the ordinary course of business, the Debtors collect, withhold, and incur income taxes, franchise taxes, sales
and use taxes, personal property taxes, foreign taxes, and other governmental and regulatory and employee-related taxes, penalties, interests, assessments, and fees (collectively, the " <u>Taxes and Fees</u> "). On April 23, 2025, the
Court entered a final order [Docket No. 303] authorizing, but not directing, the Debtors to, among other things, pay Taxes and Fees that arise or accrue in the ordinary course of business on a postpetition basis consistent with prepetition
practices. The Debtors believe that they are current with respect to any postpetition Taxes and Fees that have come due.

**Notes to Part 7: Questionnaire** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (a)</u>: Pursuant to the relief granted in the Debtors' various First Day Orders, the Debtors have
made payments on account of prepetition debts as they come due in the ordinary course of business. Where applicable, details of these payments have been delivered to the required notice parties pursuant to the reporting requirements set forth in the
First Day Orders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Item (g)</u>: Please refer to the "Debtor in Possession Financing" notes above regarding approved
postpetition financing.

------

![LOGO](g847630dsp120.jpg)

UNITED STATES BANKRUPTCY COURT Eastern DISTRICT OF Missouri In Re. 23andMe, Inc. § Case No. 25-40977 § Lead Case No. 25-40976 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 07/31/2025 Petition Date: 03/23/2025 Months Pending: 4 Industry Classification: Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Employees (current): 223 Debtor's Full-Time Employees (as of date of order for relief): 262 Supporting Documentation (check all that are attached):(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement) Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Thomas H. Riske Thomas H. Riske Signature of Responsible Party Printed Name of Responsible Party 09/02/2025 Date 120 S. Central Avenue, Suite 1800, St. Louis, Missouri 63105Address

UST Form 11-MOR (12/23/2022) 1

------

![LOGO](g847630dsp121.jpg)

Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $45,550,041 b. Total receipts (net of transfers between accounts) $278,809,209 $327,401,359 c. Total disbursements (net of transfers between accounts) $32,312,785 $87,404,866 d. Cash balance end of month (a+b-c) $292,046,466 e. Disbursements made by third party for the benefit of the estate $28,023,611 $28,023,611 f. Total disbursements for quarterly fee calculation (c+e) $60,336,396 $115,428,477 Part 2: Asset and Liability Status Current Month (Not generally applicable to Individual Debtors. See Instructions.) a. Accounts receivable (total net of allowance) $0 b. Accounts receivable over 90 days outstanding (net of allowance) $0 c. Inventory (Book Market Other (attach explanation)) $0 d Total current assets $296,936,111 e. Total assets $341,390,830 f. Postpetition payables (excluding taxes) $61,491,028 g. Postpetition payables past due (excluding taxes) $14,715,363 h. Postpetition taxes payable $24,076 i. Postpetition taxes past due $0 j. Total postpetition debt (f+h) $61,515,104 k. Prepetition secured debt $224,364 l. Prepetition priority debt $42,689 m. Prepetition unsecured debt $52,986,842 n. Total liabilities (debt) (j+k+l+m) $114,768,999 o. Ending equity/net worth (e-n) $226,621,830 Part 3: Assets Sold or Transferred Current Month Cumulative a. Total cash sales price for assets sold/transferred outside the ordinary course of business $302,500,000 $302,500,000 b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business $38,032,957 $38,032,957 c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $264,467,043 $264,467,043 Part 4: Income Statement (Statement of Operations) Current Month Cumulative (Not generally applicable to Individual Debtors. See Instructions.) a. Gross income/sales (net of returns and allowances) $3,077,867 b. Cost of goods sold (inclusive of depreciation, if applicable) $926,584 c. Gross profit (a-b) $2,151,283 d. Selling expenses $953,804 e. General and administrative expenses $2,527,167 f. Other expenses $2,109,480 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $-353,770 i. Taxes (local, state, and federal) $0 j. Reorganization items $-273,894,701 k. Prof8it 4(lo7ss6)30-001 19Sep25 11:10 Page 12$217 0,809,303 $227,684,430

UST Form 11-MOR (12/23/2022) 2

------

![LOGO](g847630dsp122.jpg)

Part 5: Professional Fees and Expenses Approved Current Month Approved Cumulative Paid Current Month Paid Cumulative a. Debtor's professional fees & expenses (bankruptcy) Aggregate Total $12,371,721 $21,589,789 $12,371,721 $21,589,789 Itemized Breakdown by Firm Firm Name Role i Alvarez & Marsal North AmericFinancial Professional $1,208,297 $3,652,178 $1,208,297 $3,652,178 ii Carmody MacDonald P.C. Local Counsel $126,810 $334,525 $126,810 $334,525 iii FTI Consulting, Inc. Other $970,788 $970,788 $970,788 $970,788 iv Goodwin Procter LLP Special Counsel $1,784,261 $3,184,261 $1,784,261 $3,184,261 v Kelley Drye & Warren LLP Other $2,100,566 $2,100,566 $2,100,566 $2,100,566 vi Kroll Restructuring Administra Other $4,674,369 $5,888,538 $4,674,369 $5,888,538 vii Lewis Rice LLC Special Counsel $25,480 $25,480 $25,480 $25,480 viii Moelis & Company, LLC Financial Professional $498,667 $1,200,970 $498,667 $1,200,970 ix Paul, Weiss, Rifkind, Wharton &Lead Counsel $902,646 $4,152,646 $902,646 $4,152,646 x Stinson LLP Other $79,837 $79,837 $79,837 $79,837 xi xii xiii xiv xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv 8xx4xv7i

UST Form 11-MOR (12/23/2022) 3

------

![LOGO](g847630dsp123.jpg)

xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii 8lxx4v7iii

UST Form 11-MOR (12/23/2022) 4

------

![LOGO](g847630dsp124.jpg)

lxxix lxxx lxxxi lxxxii lxxxiii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci b. ApprovedCurrent Month ApprovedCumulativePaid CurrentMonth PaidCumulative Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total $783,222 $1,979,414 $783,222 $1,979,414 Itemized Breakdown by Firm Firm Name Role i BDO Australia Other$0 $323 $0 $323 ii BDO USA LLP Other $9,350 $9,350 $9,350 $9,350 iii Captiva Advisory, Inc. Other$10,125 $13,076 $10,125 $13,076 iv Deloitte & Touche LLP Other$37,060 $37,060 $37,060 $37,060 v Duane Morris LLP Other $0$4,881 $0$4,881 vi FisherBroyles, LLP Other $9,504 $9,504 $9,504 $9,504 vii Foley & Lardner LLP Other$0 $0 $0 $0 viii Frank, Rimerman Co LLP Other$0 $0 $0 $0 ix Gibson, Dunn & Crutcher LLP Other$0 $0 $0 $0 x Greenberg Traurig LLP Other$0 $125,000 $0 $125,000 xi Hintze Law PLLC Other $0$0$0$0 xii KPMG LLP Other$0 $0 $0 $0 xiii McCarthy Tétrault LLP Other$151,092 $289,964 $151,092 $289,964 xiv McDonnell Boehnen Hulbert & Other$39,703 $39,703 $39,703 $39,703

UST Form 11-MOR (12/23/2022) 5

------

![LOGO](g847630dsp125.jpg)

xv McDonnell Boehnen Hulbert & LLP Other $0 $0 $0 $0 xvi Morgan, Lewis & Bockius LLP Other $76,389 $606,891 $76,389 $606,891 xvii Osler Hoskin & Harcourt LLP Other $0 $4,075 $0 $4,075 xviii Quarles & Brady LLP Other $0 $0 $0 $0 xix Reevemark, LLC Other $450,000 $838,900 $450,000 $838,900 xx Ryan, LLC Other $0 $0 $0 $0 xxi Scale Strategy Operations LLC Other $0 $0 $0 $0 xxii Sheppard Mullin Other $0 $686 $0 $686 xxiii Wilson Sonsini Goodrich & RosOther $0 $0 $0 $0 xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv 8lvi4

UST Form 11-MOR (12/23/2022) 6

------

![LOGO](g847630dsp126.jpg)

lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxviii lxxix lxxx lxxxi lxxxii lxxxiii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii

UST Form 11-MOR (12/23/2022) 7

------

![LOGO](g847630dsp127.jpg)

xcix c c. All professional fees and expenses (debtor & committees) $13,115,240 $23,529,500 $13,154,943 $23,569,203 Part 6: Postpetition Taxes Current Month Cumulative a. Postpetition income taxes accrued (local, state, and federal) $0 $0 b. Postpetition income taxes paid (local, state, and federal) $0 $0 c. Postpetition employer payroll taxes accrued $0 $165,021 d. Postpetition employer payroll taxes paid $143,026 $1,163,963 e. Postpetition property taxes paid $0 $3,036 f. Postpetition other taxes accrued (local, state, and federal) $24,076 $193,961 g. Postpetition other taxes paid (local, state, and federal) $6,973 $112,440 Part 7: Questionnaire - During this reporting period: a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No b. Were any payments made outside the ordinary course of business Yes No without court approval? (if yes, see Instructions) c. Were any payments made to or on behalf of insiders? Yes No d. Are you current on postpetition tax return filings? Yes No e. Are you current on postpetition estimated tax payments? Yes No f. Were all trust fund taxes remitted on a current basis? Yes No g. Was there any postpetition borrowing, other than trade credit? Yes No (if yes, see Instructions) h. Were all payments made to or on behalf of professionals approved by the court? Yes No N/A i. Do you have: Worker's compensation insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) General liability insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) j. Has a plan of reorganization been filed with the court? Yes No k. Has a disclosure statement been filed with the court? Yes No l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?

UST Form 11-MOR (12/23/2022) 8

------

![LOGO](g847630dsp128.jpg)

Part 8: Individual Chapter 11 Debtors (Only) a. Gross income (receipts) from salary and wages $0 b. Gross income (receipts) from self-employment $0 c. Gross income from all other sources $0 d. Total income in the reporting period (a+b+c) $0 e. Payroll deductions $0 f. Self-employment related expenses $0 g. Living expenses $0 h. All other expenses $0 i. Total expenses in the reporting period (e+f+g+h) $0 j. Difference between total income and total expenses (d-i) $0 k. List the total amount of all postpetition debts that are past due $0 l. Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)? Yes No m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A Privacy Act Statement 28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/ eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F). I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate. /s/ Joe Selsavage Signature of Responsible Party Interim Chief Executive Officer and Chief Financial and Printed Name of Responsible Party 09/02/2025 Title Date

UST Form 11-MOR (12/23/2022) 9

------

![LOGO](g847630dsp129.jpg)

Page One Part One Page One Part Two Page Two Part One Page Two Part Two

UST Form 11-MOR (12/23/2022) 10

------

![LOGO](g847630dsp130.jpg)

Bankruptcy51to100 NonBankruptcy1to50 NonBankruptcy51to100 Bankruptcy1to50

UST Form 11-MOR (12/23/2022) 11

------

![LOGO](g847630dsp131.jpg)

PageThree PageFour

UST Form 11-MOR (12/23/2022) 12

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 1** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 7/1/2025 - 7/31/2025 |
| **Cash Receipts and Disbursements** | **Cash Receipts and Disbursements** | **Cash Receipts and Disbursements** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **25-40977<br>23andMe,<br>Inc.** | **25-40976<br>23andMe<br>Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy, Inc** | **25-40980<br>Lemonaid<br>Health, Inc.** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings Inc.** | **25-40982<br>LPharm<br>CS LLC** | **25-40983<br>LPharm<br>INS LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40975**<br> **LPRXOne<br>LLC** | **25-40986**<br> **LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  Beginning bank cash balance | $45550 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total receipts | 287825 |  |  |  |  |  |  |  |  |  |  |  |
|  Total disbursements | (41328) |  |  |  |  |  |  |  |  |  |  |  |
|  **Ending bank cash balance** | $**292046** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

**Notes:** Cash Balance includes approximately $30.6M of Professional Fee Admin Reserves in the Carve Out Account.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 2** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 7/1/2025 - 7/31/2025 |
| **Balance Sheet** | **Balance Sheet** | **Balance Sheet** |

---

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Consolidated** | **25-40977<br>23andMe,<br>Inc.** | **25-40975**<br> **LPRXOne<br>LLC** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40976<br>23andMe<br>Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holding<br>Inc.** | **25-40982<br>LPharm<br>CS LLC** | **25-40983**<br> **LPharm<br>INS<br>LLC** | **25-40984**<br> **LPharm<br>RX LLC** | **25-40984<br>LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  **Assets** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **Current assets:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Cash and Cash Equivalents | $287033 | $287033 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Accounts receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Prepaid Expenses | 9927 | 9903 |  | 24 |  |  |  |  |  |  |  |  |  |
|  Inventory | 180 |  | 180 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current assets** | **297141** | **296936** | **180** | **24** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Property and equipment, net | $436 | $177 | $259 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Lease right-of-use assets, net | 87 | 73 | 14 |  |  |  |  |  |  |  |  |  |  |
|  Restricted cash | 5723 | 5723 |  |  |  |  |  |  |  |  |  |  |  |
|  Intangible assets, net | 23063 | 20264 |  | 2799 |  |  |  |  |  |  |  |  |  |
|  Other assets | 18358 | 18218 | 140 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total assets** | $**344807** | $**341391** | $**593** | $**2823** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |
|  **Liabilities** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **Current liabilities:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Accounts payable and accrued expenses | $41318 | $40410 | $432 | $476 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Deferred revenue | 695 |  | 389 | 306 |  |  |  |  |  |  |  |  |  |
|  Lease Liabilities | 1745 | 1665 | 80 |  |  |  |  |  |  |  |  |  |  |
|  Tax Payable | 43 | 43 |  |  |  |  |  |  |  |  |  |  |  |
|  Other Current Liabilities | 59 | 59 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current liabilities** | **43859** | **42177** | **901** | **782** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Other Liabilities | 224 | 224 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total liabilities not subject to compromise** | **44084** | **42401** | **901** | **782** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Liabilities subject to compromise:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Accounts payable and accrued payable | $8056 | $7929 | $61 | $65 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Lease liabilities | 18104 | 18104 |  |  |  |  |  |  |  |  |  |  |  |
|  Loss contingencies | 46310 | 46310 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total liabilities** | **116554** | **114745** | **962** | **847** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Common Stock | $3 | $3 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Additional paid-in capital | 2434938 | 2434938 |  |  |  |  |  |  |  |  |  |  |  |
|  Accumulated Deficit - Retained Earnings | (67064) | (67064) |  |  |  |  |  |  |  |  |  |  |  |
|  Accumulated Deficit - Net Income | (2139623) | (2139623) |  |  |  |  |  |  |  |  |  |  |  |
|  **Total liabilities and equity** | $**344807** | $**342998** | $**962** | $**847** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

**Notes:** The Debtors maintain their books and records on a consolidated basis in the ordinary course of business, however, this MOR was prepared on an entity-by-entity basis. Accordingly, column "Consolidated" was included to provide a consolidated view of the Balance Sheet for reconciliation purposes only.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 3** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 7/1/2025 - 7/31/2025 |
| **Income Statement** | **Income Statement** | **Income Statement** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **25-40977<br>23andMe,<br>Inc.** | **25-40975**<br>**LPRXOne<br>LLC** | **25-40980<br>Lemonaid<br>Health,<br>Inc.** | **25-40976**<br>**23andMe<br>Holding<br>Co.** | **25-40978<br>23andMe<br>Pharmacy<br>Holdings,<br>Inc.** | **25-40979<br>Lemonaid<br>Community<br>Pharmacy,<br>Inc** | **25-40981<br>Lemonaid<br>Pharmacy<br>Holdings<br>Inc.** | **25-40982<br>LPharm<br>CS LLC** | **25-40983<br>LPharm<br>INS<br>LLC** | **25-40984<br>LPharm<br>RX LLC** | **25-40986<br>LPRXTwo<br>LLC** | **25-40985<br>LPRXThree<br>LLC** |
|  **Revenue:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Total consumer services revenue | $2395 | $— | $278 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total research services and other revenue | 683 |  |  |  |  |  |  |  |  |  |  |  |
|  Total product revenue |  | 1509 |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total revenue** | **3078** | **1509** | **278** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Expenses:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Cost of revenue | $927 | $723 | $759 | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Sales and marketing | 954 |  |  |  |  |  |  |  |  |  |  |  |
|  General and administrative | 2527 |  |  |  |  |  |  |  |  |  |  |  |
|  Research and development | 2109 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total expenses** | **6516** | **723** | **759** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Income (Loss) from operations | $(3438) | $785 | $(480) | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  **Interest and other (expense) income:** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Total - Interest income | $354 | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Total - Other (expense) income | (1) |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total interest and other (expense) income** | **353** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  **Reorganization items** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Professional fees | $(4821) | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— | $— |
|  Board fees | $(197) |  |  |  |  |  |  |  |  |  |  |  |
|  Legal fees | $(12785) |  |  |  |  |  |  |  |  |  |  |  |
|  Public Relations | $(297) |  |  |  |  |  |  |  |  |  |  |  |
|  Gain/Loss on Sale of Subsidiary | $291995 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total Reorganization item gain (losses)** | **273895** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
|  Net Loss | $270809 | $785 | $(480) | $— | $— | $— | $— | $— | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Net income (loss)** | $**270809** | $**785** | $**(480)** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 4** |
| **In re: 23andMe Inc.** | Lead Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 7/1/2025 - 7/31/2025 |
| **Postpetition Liabilities Aging** | **Postpetition Liabilities Aging** | **Postpetition Liabilities Aging** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Day Past Due** | **Day Past Due** | **Day Past Due** | **Day Past Due** | **Day Past Due** | |
|  | **Current** | **1 - 30** | **31 - 60** | **61 - 90** | **91+** | **Total** |
|  Accounts payable and accrued expenses | 47042 | 11383 | 1072 | 1932 | 62 | 61491 |
|  Deferred revenue |  |  |  |  |  |  |
|  Lease Liabilities |  |  |  |  |  |  |
|  Other Current Liabilities |  |  |  |  |  |  |
|  DIP Lending |  |  |  |  |  |  |
|  Other Liabilities |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total postpetition liabilities** | **47042** | **11383** | **1072** | **1932** | **62** | **61491** |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 5** |
| **In re: 23andMe Inc.** | Lead Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 7/1/2025 - 7/31/2025 |
| **Schedule of Asset Sales** | **Schedule of Asset Sales** | **Schedule of Asset Sales** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Entity** | **Asset** | **Date of Sale** | **Gross Sales Price** |
|  23andMe Inc. | All of the properties, rights, title, interests and other tangible and intangible assets that Sellers own or possess, other than the Excluded Assets, wherever located and whether or not required to be reflected on a balance sheet | 7/14/2025 | $302500000 |
|  Less: Allowable Expenses |  |  | $(38032957) |
|  Net Sale Price |  |  | $264467043 |

---

<u>Notes</u> 

- Detailed description of the assets encompassed as "Acquired Assets" are outlined in the Asset Purchase Agreement, dated as of June 13, 2025, by and among Chrome Holding Co. f/k/a 23andMe Holding Co., the Additional Sellers (as defined therein), and 23andMe Research Institute f/k/a TTAM Research Institute

- Allowable Expenses include the DIP Repayment, lender fees, and expenses, breakup fee, and other professional fees

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 6** |
| **In re: 23andMe Inc.** | Lead Case No.: | 25-40977 |
| ($ in 000s) | Reporting Period: | 7/1/2025 - 7/31/2025 |
| **Payments to Insiders** | **Payments to Insiders** | **Payments to Insiders** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Case No.** | **Entity** | **Recipient** | **Total Payments** |
| 25-40977 | 23andMe Inc. | Officer #1 | $52 |
| 25-40977 | 23andMe Inc. | Officer #2 | $41 |
| 25-40977 | 23andMe Inc. | Director #5 | $3 |
|  |  | **Total** | $**96** |

---

**<u>Notes:</u>**

With respect to insiders, all cash payments made were on account of ordinary course salaries and/or fees, benefits, authorized travel, and and expense reimbursements.

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 7** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 7/1/2025 - 7/31/2025 |
| **Certification Regarding Postpetition Taxes** | **Certification Regarding Postpetition Taxes** | **Certification Regarding Postpetition Taxes** |

---

The Debtors hereby submit this attestation regarding postpetition tax payments during the period of July 1 through July 31, 2025.

The Debtors are authorized to pay Taxes and Fees that arise or accrue in the ordinary course of business on a postpetition basis consistent with prepetition practices. The Debtors believe that they are current with respect to any postpetition Taxes and Fees that have come due.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 9/2/2025 |
| Signature of Authorized Individual | Date |
| Joe Selsavage | 9/2/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 8** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 7/1/2025 - 7/31/2025 |
| **Schedule of Pre-Petition Payments** | **Schedule of Pre-Petition Payments** | **Schedule of Pre-Petition Payments** |

---

The Debtors hereby submit this attestation regarding prepetition payments during the period of July 1 through July 31, 2025

All payments made by the Debtors during the period of July 1 through July 31, 2025 (and included in the disbursements reported herein), were authorized under First Day Orders granted by the Court.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 9/2/2025 |
| Signature of Authorized Individual | Date |

---

---

| | |
|:---|:---|
| Joe Selsavage | 9/2/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 9** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 7/1/2025 - 7/31/2025 |
| **Schedule of Payments to Insiders** | **Schedule of Payments to Insiders** | **Schedule of Payments to Insiders** |

---

The Debtors hereby submit this attestation regarding prepetition payments during the period of July 1 through July 31, 2025

With respect to insiders, all cash payments made were on account of ordinary course salaries and/or fees, benefits, authorized travel and expense reimbursements.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 9/2/2025 |
| Signature of Authorized Individual | Date |

---

---

| | |
|:---|:---|
| Joe Selsavage | 9/2/2025 |
| Printed Name of Authorized Individual | Date |

---

------

---

| | | |
|:---|:---|:---|
|  |  | **Exhibit - 10** |
| **In re: 23andMe Inc., et al.** | Lead Case No.: | 25-40976 |
| ($ in 000s) | Reporting Period: | 7/1/2025 - 7/31/2025 |
| **All Bank Statements and Bank Reconciliations for the Reporting Period** | **All Bank Statements and Bank Reconciliations for the Reporting Period** | **All Bank Statements and Bank Reconciliations for the Reporting Period** |

---

The Debtors hereby submit this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and journal entries.

The Debtors' standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting period. I attest that each of the Debtors' bank accounts has been reconciled in accordance with their standard practices.

---

| | |
|:---|:---|
| /s/ Joe Selsavage | 9/2/2025 |
| Signature of Authorized Individual | Date |

---

---

| | |
|:---|:---|
| Joe Selsavage | 9/2/2025 |
| Printed Name of Authorized Individual | Date |

---